Tirzepatide Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

190

Total Trials

Recruiting

Completed

1,260,159

Total Enrollment

States

Tirzepatide Evidence & Publications

239 peer-reviewed publications + per-arm primary-outcome data from 27 pivotal trials.

See published evidence →

Tirzepatide Clinical Trials

Sortable list of all 190 Tirzepatide trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

Tirzepatide History and Updates

Every FDA approval, label revision, recall, trial milestone, and pivotal publication for Tirzepatide — sourced from openFDA, ClinicalTrials.gov, and PubMed.

See full history →

Recent Tirzepatide updates

See full history →

Tirzepatide Phase 3 Study for Weight Reduction Maintenance Completes Primary· Jan 20, 2026
Mounjaro (Tirzepatide) Receives FDA Supplemental Efficacy Approval· Dec 19, 2025
Tirzepatide Monotherapy Shows Significant HbA1c Reduction in Type 2 Diabetes· Oct 21, 2025
Tirzepatide Significantly Lowers HbA1c in Pediatric Type 2 Diabetes· Sep 26, 2025
Tirzepatide Phase 1 Pediatric Obesity Trial Shows High TEAE Incidence· Aug 26, 2025
Tirzepatide SUMMIT Trial for HFpEF and Obesity Improves KCCQ Scores, Reduces…· Aug 20, 2025
Tirzepatide Phase 3 Trial in Chinese Type 2 Diabetes Lowers HbA1c· Aug 8, 2025
Tirzepatide Reduces Obstructive Sleep Apnea Severity in Phase 3 Trial· Apr 30, 2025

What Is Tirzepatide?

Tirzepatide is an FDA-approved medication for weight management in adults with obesity or overweight, and for the treatment of type 2 diabetes. It is a dual agonist, meaning it activates two types of receptors in the body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). By activating these receptors, tirzepatide helps to improve blood sugar control and can lead to significant weight loss.

Beyond its approved uses, tirzepatide is being investigated for a range of other conditions. These include its potential to help adults with type 1 diabetes manage insulin use, improve ovarian dysfunction in women with polycystic ovary syndrome (PCOS), and treat alcohol use disorder. Researchers are also studying its effects on muscle mass and vascular health in older adults with obesity, and its role in slowing kidney growth in autosomal dominant polycystic kidney disease (ADPKD). Additionally, it is being explored for weight management in survivors of childhood acute lymphoblastic leukemia (ALL) and individuals with methamphetamine use disorder.

Uses and Conditions Under Study

Tirzepatide is being studied for a variety of health conditions, with a primary focus on metabolic disorders and weight management.

Obesity and Overweight: A significant number of trials, totaling 118 studies, are investigating tirzepatide for obesity and overweight. This includes general obesity, overweight, and specific conditions like obesity disorder. Tirzepatide has shown promising results in promoting weight loss, with some studies reporting up to 22% weight loss in individuals with obesity.
Type 2 Diabetes: Tirzepatide is also extensively studied for type 2 diabetes, with 44 trials focusing on this condition. As a GIP and GLP-1 receptor agonist, it helps improve glucose control and can lead to weight reduction in patients with type 2 diabetes, though weight loss may be around 15% in this population.
Alcohol Use Disorder: There are 3 trials exploring tirzepatide's potential in treating alcohol use disorder. GLP-1 receptor agonists have shown promise in this area, and tirzepatide's dual action may offer additional benefits.
Polycystic Ovary Syndrome (PCOS): Tirzepatide is being examined in women with PCOS who are overweight or have obesity, with studies evaluating its effects on ovarian dysfunction.
Type 1 Diabetes: Research is underway to determine if tirzepatide can help adults with type 1 diabetes reduce the need for carbohydrate counting and simplify insulin pump management.
Kidney Disease: Studies are investigating whether tirzepatide can slow kidney growth in adults with autosomal dominant polycystic kidney disease (NCT05792942).
Other Conditions: Tirzepatide is also being studied for its effects on muscle mass and vascular health in older adults with obesity, and for weight management in survivors of childhood acute lymphoblastic leukemia. Additionally, its use is being explored in individuals with methamphetamine use disorder and those with atrial fibrillation (AFIB) where weight loss is a key treatment strategy.

Some studies also include healthy participants, often to assess the drug's safety, how it moves through the body, and how it is processed.

Dosing

Tirzepatide is typically administered as a weekly subcutaneous injection. The dosing often begins at a lower strength and is gradually increased based on patient tolerance and therapeutic response, a process known as titration.

A common titration schedule observed in studies involves starting with 2.5 mg once weekly for 4 weeks. The dose is then increased every 4 weeks to the next strength, progressing through:

5.0 mg once weekly
7.5 mg once weekly
10.0 mg once weekly
12.5 mg once weekly
15 mg once weekly (which is often the maximum studied dose)

This titration allows the body to adjust to the medication and helps manage potential side effects. The decision to increase the dose is often made in consultation with a healthcare provider, considering a participant's individual response and tolerance.

In addition to these standard adult doses, investigational studies are exploring weight-based dosing for specific populations. For instance, some cohorts are being studied with doses ranging from 1.25 mg to 2.5 mg for individuals weighing less than 50 kg, and 2.5 mg to 5 mg for those weighing 40 to 60 kg or 50 kg and above. Other doses, such as 1 mg, 4 mg, 8 mg, and 12 mg, have also been investigated in various study arms.

Side Effects

In clinical trials involving patients taking Tirzepatide, the most common side effects were related to the digestive system. These effects were generally mild to moderate and often decreased over time.

25.0% of patients taking Tirzepatide experienced nausea, compared to 8.0% on placebo.
20.8% of patients taking Tirzepatide experienced diarrhea, compared to 8.4% on placebo.
13.7% of patients taking Tirzepatide experienced constipation, compared to 4.4% on placebo.
12.4% of patients taking Tirzepatide experienced decreased appetite, compared to 2.8% on placebo.
11.4% of patients taking Tirzepatide experienced vomiting, compared to 2.5% on placebo.
7.8% of patients taking Tirzepatide experienced dyspepsia (indigestion), compared to 2.6% on placebo.
5.9% of patients taking Tirzepatide experienced abdominal pain, compared to 2.7% on placebo.
5.8% of patients taking Tirzepatide experienced an injection site reaction, compared to 0.5% on placebo.

Other reported side effects included headache (6.5% on Tirzepatide vs 5.8% on placebo) and gastroesophageal reflux disease (5.6% on Tirzepatide vs 1.4% on placebo).

Clinical Trial Results

Clinical trials have investigated the effectiveness of Tirzepatide in managing Type 2 Diabetes and related conditions, focusing on blood sugar control and body weight reduction.

Blood Sugar Control and Weight Management in Type 2 Diabetes

In a study (NCT03131687) involving participants with Type 2 Diabetes, Tirzepatide demonstrated significant, dose-dependent improvements over 26 weeks:

Patients receiving 15 mg Tirzepatide experienced an average reduction in HbA1c of 2.4% from baseline, compared to a 0.1% increase in the placebo group and a 1.1% reduction with 1.5 mg Dulaglutide. Lower doses of Tirzepatide also showed substantial reductions (e.g., 5 mg reduced HbA1c by 1.6%).
A high percentage of patients achieved target HbA1c levels. For instance, 90.0% of patients on 10 mg Tirzepatide and 77.4% on 15 mg Tirzepatide reached an HbA1c target of less than 7.0%, compared to 11.8% on placebo.
Participants on 15 mg Tirzepatide achieved an average body weight loss of 11.3 kilograms (kg), compared to a 0.4 kg loss in the placebo group and a 2.7 kg loss with 1.5 mg Dulaglutide.
Significant weight loss was also observed, with 70.6% of patients on 10 mg Tirzepatide and 62.3% on 15 mg Tirzepatide achieving 5% or greater body weight loss from baseline, compared to 0% on placebo.
Fasting blood glucose levels also saw significant reductions, with 10 mg Tirzepatide reducing levels by 60.7 mg/dL and 15 mg Tirzepatide by 57.5 mg/dL, while placebo levels increased by 15.5 mg/dL.

Another study (NCT03311724) further supported these findings in Type 2 Diabetes patients:

Various Tirzepatide dosing regimens led to HbA1c reductions ranging from 1.7% to 2.0%, compared to a 0.2% increase with placebo.
Body weight reductions were consistent, averaging between 5.3 kg and 5.7 kg across different Tirzepatide regimens, versus a 0.5 kg reduction with placebo.
Up to 87% of patients on Tirzepatide achieved an HbA1c target of less than 7.0%, compared to 10% on placebo.
The incidence of hypoglycemia (low blood sugar) was very low, with 0 to 1 episodes reported across all Tirzepatide and placebo groups.

Results in Japanese Participants with Type 2 Diabetes

A study specifically in Japanese participants with Type 2 Diabetes (NCT03322631) showed similar positive effects:

Fasting plasma glucose was significantly reduced by 51.7 mg/dL to 77.5 mg/dL across different Tirzepatide cohorts, compared to a 4.0 mg/dL reduction in the placebo group.
No serious adverse events related to the study drug were reported in any group.

Early Phase Pharmacodynamic Data

An early phase study (NCT02759107) in healthy participants and those with Type 2 Diabetes explored how Tirzepatide affects the body. Higher doses of Tirzepatide reduced the overall glucose exposure (AUC of glucose) by up to 43% by Day 23. No serious adverse events were reported for Tirzepatide in this study.

Currently Recruiting Trials

Many clinical trials are currently recruiting participants to explore the potential benefits of tirzepatide across a wide range of health conditions. These studies aim to understand how this medication, initially approved for diabetes and obesity, might help with other related or even novel indications. One Phase 4 study, NCT07218445, sponsored by Mayo Clinic, is investigating the effect of tirzepatide on menopausal vasomotor symptoms (hot flashes) and biological aging in post-menopausal women with obesity. This study seeks to enroll 40 participants. For those with obesity-driven endometrial cancer, the UNC Lineberger Comprehensive Cancer Center is sponsoring an Early Phase 1 study, NCT07065552, to examine tirzepatide's antiproliferative effect on the endometrium, with an enrollment target of 20 participants. St. Jude Children's Research Hospital is conducting a Phase 2 trial, NCT07228741, combining tirzepatide with resistance exercise for cardiometabolic health in 20 adult survivors of childhood acute lymphoblastic leukemia (ALL) who live with obesity or overweight. Another Phase 2 study, NCT06811324, from The University of Texas Health Science Center at San Antonio, is evaluating the effects of tirzepatide on muscle and vascular health in 20 obese older adults. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is sponsoring a Phase 2 study, NCT07046819, to assess tirzepatide in 120 participants with Metabolic Alcohol-associated Liver Disease (MetALD) and Alcohol Use Disorder. In a large Phase 3 study, NCT07481747 (SURMOUNT-1), Hudson Biotech is evaluating the efficacy and safety of tirzepatide versus placebo in 2539 participants who are obese or overweight without diabetes but with weight-related comorbidities. Eli Lilly and Company is also sponsoring a significant Phase 3 study, NCT07165028 (SYNERGY-Outcomes), which aims to prevent major adverse liver outcomes in 4500 adults with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). For individuals with obesity and knee osteoarthritis, the University of Melbourne is conducting a Phase 4 study, NCT06191848, to see if tirzepatide can reduce the need for knee replacement in 352 participants. Furthermore, Eli Lilly is investigating tirzepatide in 300 adolescents with obesity and weight-related comorbidities in the Phase 3 SURMOUNT-ADOLESCENTS-2 study, NCT06439277.

Where to Participate

Clinical trials for tirzepatide are widely accessible, with recruiting sites spanning across the United States and beyond. There are currently 355 sites in 263 cities across 43 states actively seeking participants. This broad geographic reach helps ensure diverse populations can contribute to research. Some of the cities with the most recruiting locations include:

San Antonio, Texas (12 sites)
Houston, Texas (10 sites)
New York, New York (9 sites)
Miami, Florida (7 sites)
Orlando, Florida (7 sites)
Chicago, Illinois (6 sites)
Tucson, Arizona (5 sites)
Austin, Texas (5 sites)
Indianapolis, Indiana (5 sites)
Greenville, South Carolina (4 sites)

Eligibility for these studies is generally inclusive, welcoming individuals aged from 12 to 100 years. Participants of all genders are invited to join, and many studies also accept healthy volunteers. Specific trials are designed for children and adolescents, reflecting the broad scope of tirzepatide research.

Development Timeline

The journey of tirzepatide in clinical research began on May 3, 2016, with its first clinical trial. Since then, the development program has grown substantially, encompassing a total of 190 clinical trials that have collectively enrolled over 1.2 million participants. This extensive research effort has been largely driven by Eli Lilly and Company, which sponsors the majority of studies. Initially, tirzepatide's development focused on conditions like irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia. However, its potential quickly became evident, leading to a significant expansion into metabolic disorders. The drug rapidly progressed through clinical phases, with a substantial number of studies in Phase 2 (51 trials) and Phase 3 (42 trials), demonstrating its advancement towards potential regulatory approvals. The scope of conditions under investigation for tirzepatide has broadened dramatically over time. Following its success in Type 2 Diabetes and obesity, researchers began exploring its effects on a wide array of related health issues. This includes conditions such as Type 1 Diabetes, various forms of cancer (endometrial, prostate, breast), cardiovascular diseases like coronary artery disease and atrial fibrillation, liver conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD), and even neurological and psychiatric disorders like alcohol use disorder and schizophrenia. The latest trials are projected to run until May 2026, indicating ongoing commitment to understanding the full therapeutic potential of tirzepatide.

Tirzepatide Development Timeline

Clinical trial activity from 2016 to 2026.

2026

NCT06180616PHASE2not yet recruiting

Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

40 enrolled

NCT07468552PHASE2not yet recruiting

Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

100 enrolled

NCT07298915PHASE3not yet recruiting

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

24 enrolled

NCT07078838PHASE2not yet recruiting

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

40 enrolled

NCT06732245PHASE2not yet recruiting

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

224 enrolled

NCT07573163PHASE2not yet recruiting

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

34 enrolled

NCT07349641PHASE2not yet recruiting

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

55 enrolled

NCT07265752PHASE2not yet recruiting

Tirzepatide for the Treatment of Cannabis Use Disorder

6 enrolled

NCT06820281PHASE2not yet recruiting

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

44 enrolled

NCT07554638PHASE4not yet recruiting

Incretin Therapies in Obesity-related HFpEF

50 enrolled

NCT07567378not yet recruiting

CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

30 enrolled

NCT07559500PHASE1recruiting

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

176 enrolled

NCT07284511PHASE2/PHASE3recruiting

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

105 enrolled

NCT07382024NAnot yet recruiting

Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation

200 enrolled

NCT07179120PHASE2not yet recruiting

Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

180 enrolled

NCT07555730PHASE4not yet recruiting

AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)

400 enrolled

NCT07065552EARLY_PHASE1recruiting

Tirzepatide in Obesity-Driven Endometrial Cancer

20 enrolled

NCT07228741PHASE2recruiting

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

20 enrolled

NCT07527910PHASE2not yet recruiting

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

204 enrolled

NCT07218445PHASE4recruiting

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

40 enrolled

NCT07257484PHASE4not yet recruiting

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

30 enrolled

NCT06811324PHASE2recruiting

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

20 enrolled

NCT07504172not yet recruiting

Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

1,700 enrolled

NCT07046819PHASE2recruiting

Tirzepatide in MetALD

120 enrolled

NCT07483801PHASE4not yet recruiting

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

112 enrolled

NCT07492563not yet recruiting

Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay

300 enrolled

NCT07521631PHASE2recruiting

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

372 enrolled

NCT07443956NArecruiting

Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

45 enrolled

NCT07463846PHASE1/PHASE2recruiting

A Study to Evaluate ALN-2232 in Participants With Obesity

156 enrolled

NCT07191873PHASE4not yet recruiting

Tirzepatide in Idiopathic Intracranial Hypertension Trial

60 enrolled

NCT07438444PHASE4recruiting

A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

344 enrolled

NCT07095517PHASE1recruiting

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

20 enrolled

NCT07481747PHASE3recruiting

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

2,539 enrolled

NCT07176663NAnot yet recruiting

Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure

15 enrolled

NCT07373834NArecruiting

Tirzepatide and Muscle Outcomes in Obesity

30 enrolled

NCT07364175NArecruiting

A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

60 enrolled

NCT06651177PHASE2recruiting

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

310 enrolled

NCT07417618active not recruiting

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

60,000 enrolled

NCT07202247PHASE2recruiting

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

60 enrolled

NCT07292519PHASE2not yet recruiting

Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)

46 enrolled

NCT07299084PHASE1active not recruiting

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

40 enrolled

NCT07423247PHASE4recruiting

Tirzepatide (Spartina) in Obese Kidney Transplant Recipients

30 enrolled

2025

NCT07319975NAnot yet recruiting

Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

48 enrolled

NCT07326111PHASE4recruiting

A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese

198 enrolled

NCT07247084PHASE4recruiting

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

3,000 enrolled

NCT06935838PHASE2recruiting

Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

12 enrolled

NCT05933499PHASE2recruiting

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

63 enrolled

NCT07245771PHASE1/PHASE2recruiting

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

104 enrolled

NCT07128082PHASE2active not recruiting

The Long COVID Treatment Trial

1,000 enrolled

NCT07165028PHASE3recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

4,500 enrolled

NCT07154719PHASE4recruiting

GLP-1R Actions on Muscle and the Skeleton

50 enrolled

NCT06994338PHASE2recruiting

Tirzepatide for Alcohol Use Disorder

42 enrolled

NCT06801015PHASE4active not recruiting

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

30 enrolled

NCT07099742not yet recruiting

Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)

364 enrolled

NCT07203677completed

Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)

49,065 enrolled

NCT06847399PHASE2recruiting

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

105 enrolled

NCT06727331PHASE2recruiting

Study of Tirzepatide for Recovery and Alcohol Use Management

20 enrolled

NCT07091734PHASE2recruiting

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

32 enrolled

NCT07096908PHASE4recruiting

Tirzepatide Use in People With Obesity and Type 1 Diabetes

60 enrolled

NCT06861439PHASE4active not recruiting

GLP-1s to Enhance Lasting Optimal Weight

40 enrolled

NCT06759701EARLY_PHASE1recruiting

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

30 enrolled

NCT06934642EARLY_PHASE1recruiting

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

8 enrolled

NCT06937099PHASE3recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

290 enrolled

NCT06937086PHASE3recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

350 enrolled

NCT07000955PHASE1/PHASE2active not recruiting

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

98 enrolled

NCT07293325NArecruiting

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

66 enrolled

NCT06901349PHASE2withdrawn

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

0 enrolled

NCT06976853PHASE2recruiting

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

60 enrolled

NCT06962280PHASE3active not recruiting

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

465 enrolled

NCT06965413PHASE2active not recruiting

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

285 enrolled

NCT06939088PHASE2recruiting

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

108 enrolled

NCT07057310PHASE4enrolling by invitation

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

30 enrolled

NCT06901245PHASE4recruiting

Tirzepatide in PWS, HO and GNSO

36 enrolled

NCT06914895PHASE3active not recruiting

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

905 enrolled

NCT06916065PHASE1completed

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

188 enrolled

NCT06802081PHASE2recruiting

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

100 enrolled

NCT06911203PHASE2recruiting

A Study of BGM0504 in Participants With Obesity

90 enrolled

NCT06721507PHASE4recruiting

2024 Tirzepatide-Bariatric Surgery

50 enrolled

NCT06890611PHASE1completed

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

125 enrolled

NCT06857942PHASE4recruiting

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

200 enrolled

NCT06893211PHASE2active not recruiting

Effect of Tirzepatide on Brown Adipose Tissue in Obesity

35 enrolled

NCT06582875PHASE2recruiting

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

126 enrolled

NCT06864026PHASE4recruiting

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

200 enrolled

NCT06774079PHASE4recruiting

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

24 enrolled

NCT06630585PHASE3recruiting

GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

42 enrolled

NCT06737042PHASE2not yet recruiting

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

285 enrolled

NCT06745128PHASE2active not recruiting

Tirzepatide for Obesity and Meth Use Disorder

45 enrolled

NCT07382180completed

Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients

254 enrolled

NCT06803888PHASE4active not recruiting

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

125 enrolled

NCT06914154completed

Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data

11,265 enrolled

NCT06914141completed

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

28,118 enrolled

NCT06657209PHASE4recruiting

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

104 enrolled

NCT06918405PHASE3active not recruiting

Efficacy and Safety of Tirzepatide for Weight Management

440 enrolled

NCT06980623active not recruiting

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

26,000 enrolled

2024

NCT06751589EARLY_PHASE1recruiting

A Study of a Weight Loss Intervention in People With Endometrial Cancer

36 enrolled

NCT07303556NAactive not recruiting

Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs

120 enrolled

NCT06700538PHASE1/PHASE2recruiting

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

180 enrolled

NCT06648031PHASE1completed

Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

148 enrolled

NCT06517212PHASE2recruiting

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

48 enrolled

NCT06191848PHASE4recruiting

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

352 enrolled

NCT06246799PHASE3recruiting

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

256 enrolled

NCT06534411PHASE3active not recruiting

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

1,023 enrolled

NCT06662383PHASE3active not recruiting

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

800 enrolled

NCT06779929completed

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

70,000 enrolled

NCT06518837PHASE2recruiting

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

40 enrolled

NCT06162715PHASE2/PHASE3enrolling by invitation

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

30 enrolled

NCT06643728PHASE2active not recruiting

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

252 enrolled

NCT06635057PHASE4completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

166 enrolled

NCT07096063completed

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

887,132 enrolled

NCT06606821PHASE4recruiting

The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

124 enrolled

NCT07088718completed

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

44,671 enrolled

NCT06588283PHASE3active not recruiting

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

250 enrolled

NCT06588296PHASE3completed

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

279 enrolled

NCT06603571PHASE2active not recruiting

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

350 enrolled

NCT06485089completed

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

25 enrolled

NCT06565611PHASE2active not recruiting

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

108 enrolled

NCT06515418PHASE2terminated

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

204 enrolled

NCT06439277PHASE3recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

300 enrolled

NCT06445075PHASE2completed

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

102 enrolled

NCT06373146PHASE2completed

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

392 enrolled

NCT06297616PHASE1completed

A Study of LY3841136 in Japanese Participants With Obesity or Overweight

128 enrolled

NCT06345066PHASE1completed

A Study of LY3841136 in Overweight and Obese Participants

96 enrolled

NCT06326060PHASE2completed

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

354 enrolled

NCT06301256NAunknown

Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa

20 enrolled

NCT06221969PHASE3completed

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

1,024 enrolled

NCT05708859PHASE4recruiting

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

120 enrolled

NCT05659368PHASE2unknown

Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1

10 enrolled

2023

NCT06131437PHASE3completed

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

809 enrolled

NCT06143956PHASE2recruiting

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

1,481 enrolled

NCT05912621PHASE2recruiting

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

66 enrolled

NCT06075667PHASE3active not recruiting

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

150 enrolled

NCT06037252PHASE2active not recruiting

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

414 enrolled

NCT06047548PHASE3completed

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

441 enrolled

NCT07309094recruiting

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

250 enrolled

NCT06009653PHASE4withdrawn

Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

0 enrolled

NCT05963022PHASE3completed

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

206 enrolled

NCT05990374NAunknown

Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

100 enrolled

NCT05978713PHASE1completed

A Study of Tirzepatide (LY3298176) in Healthy Lactating Females

11 enrolled

NCT06354101withdrawn

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

0 enrolled

NCT05756764active not recruiting

Anti-obesity Pharmacotherapy and Inflammation

30 enrolled

NCT05822544PHASE1recruiting

Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

564 enrolled

NCT05822830PHASE3completed

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

751 enrolled

NCT05810597PHASE1completed

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

65 enrolled

NCT05706506PHASE4completed

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

152 enrolled

NCT05536804PHASE2active not recruiting

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

140 enrolled

NCT05696847PHASE1completed

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

28 enrolled

NCT05691712PHASE3completed

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

257 enrolled

2022

NCT05564039PHASE4completed

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

282 enrolled

NCT05582096PHASE1completed

A Study of LY3457263 in Obese Participants

38 enrolled

NCT05556512PHASE3active not recruiting

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

15,374 enrolled

NCT05766358completed

Role Of Metabolic Adaptation In Weight Regain

27 enrolled

NCT05433584PHASE4active not recruiting

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

780 enrolled

NCT05412004PHASE3completed

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

469 enrolled

NCT05260021PHASE3completed

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

99 enrolled

NCT05553093PHASE4recruiting

Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

150 enrolled

2021

NCT05024032PHASE3completed

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

210 enrolled

NCT04844918PHASE3completed

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

267 enrolled

NCT04847557PHASE3completed

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

731 enrolled

NCT04660643PHASE3completed

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

783 enrolled

NCT04657016PHASE3completed

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

579 enrolled

NCT04657003PHASE3completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

938 enrolled

2020

NCT04235959PHASE1completed

A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus

24 enrolled

NCT04537923PHASE3completed

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

1,428 enrolled

NCT04407234PHASE1completed

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

36 enrolled

NCT04311411PHASE1completed

A Study of Tirzepatide in Overweight and Very Overweight Participants

114 enrolled

NCT04311424PHASE1completed

Study of Tirzepatide in Healthy Participants

6 enrolled

NCT04081337PHASE1completed

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

55 enrolled

NCT04255433PHASE3completed

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

13,299 enrolled

NCT04172987PHASE1completed

A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

40 enrolled

NCT04050553PHASE1completed

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus

42 enrolled

2019

NCT04093752PHASE3completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

917 enrolled

NCT04184622PHASE3completed

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

2,539 enrolled

NCT04166773PHASE2completed

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

190 enrolled

NCT04050670PHASE1completed

A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes

54 enrolled

NCT04039503PHASE3completed

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

475 enrolled

NCT04004988PHASE1completed

A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants

47 enrolled

NCT03987919PHASE3completed

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

1,879 enrolled

NCT03940742PHASE1completed

A Study of Tirzepatide in Participants With Impaired Liver Function

32 enrolled

NCT03951753PHASE1completed

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

117 enrolled

NCT03954834PHASE3completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

478 enrolled

NCT03861052PHASE3completed

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

636 enrolled

NCT03882970PHASE3completed

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

1,444 enrolled

NCT03861039PHASE3completed

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

443 enrolled

2018

NCT03730662PHASE3completed

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

2,002 enrolled

NCT03482024PHASE1completed

A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

45 enrolled

2017

NCT03375463PHASE1completed

A Study of Tirzepatide (LY3298176) in Healthy Participants

52 enrolled

NCT03322631PHASE1completed

A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

48 enrolled

NCT03311724PHASE2completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

111 enrolled

NCT03131687PHASE2completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

318 enrolled

2016

NCT02759107PHASE1completed

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

142 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Obesity	NCT07554638	Incretin Therapies in Obesity-related HFpEF	not yet recruiting	PHASE4	50
	NCT07218445	The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity	recruiting	PHASE4	40
	NCT07065552	Tirzepatide in Obesity-Driven Endometrial Cancer	recruiting	EARLY_PHASE1	20
	NCT07228741	Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity	recruiting	PHASE2	20
	NCT07492563	Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay	not yet recruiting	N/A	300
	NCT07521631	Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes	recruiting	PHASE2	372
	NCT07463846	A Study to Evaluate ALN-2232 in Participants With Obesity	recruiting	PHASE1/PHASE2	156
	NCT07438444	A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity	recruiting	PHASE4	344
	NCT07481747	Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)	recruiting	PHASE3	2,539
	NCT07176663	Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure	not yet recruiting	NA	15
	NCT07299084	A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus	active not recruiting	PHASE1	40
	NCT07319975	Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity	not yet recruiting	NA	48
	NCT07247084	A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)	recruiting	PHASE4	3,000
	NCT05933499	Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity	recruiting	PHASE2	63
	NCT07154719	GLP-1R Actions on Muscle and the Skeleton	recruiting	PHASE4	50
	NCT06801015	Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions	active not recruiting	PHASE4	30
	NCT07099742	Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)	not yet recruiting	N/A	364
	NCT07096908	Tirzepatide Use in People With Obesity and Type 1 Diabetes	recruiting	PHASE4	60
	NCT06861439	GLP-1s to Enhance Lasting Optimal Weight	active not recruiting	PHASE4	40
	NCT06934642	Effect of Tirzepatide on Markers of MASLD in Patients With Obesity	recruiting	EARLY_PHASE1	8
	NCT07000955	Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity	active not recruiting	PHASE1/PHASE2	98
	NCT06901349	A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes	withdrawn	PHASE2	0
	NCT06962280	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	active not recruiting	PHASE3	465
	NCT06965413	A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity	active not recruiting	PHASE2	285
	NCT07057310	Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	enrolling by invitation	PHASE4	30
	NCT06914895	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	active not recruiting	PHASE3	905
	NCT06916065	A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity	completed	PHASE1	188
	NCT06802081	TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation	recruiting	PHASE2	100
	NCT06911203	A Study of BGM0504 in Participants With Obesity	recruiting	PHASE2	90
	NCT06893211	Effect of Tirzepatide on Brown Adipose Tissue in Obesity	active not recruiting	PHASE2	35
	NCT06582875	Glucagon-Like Peptide-1 Receptor Agonist in ADPKD	recruiting	PHASE2	126
	NCT06745128	Tirzepatide for Obesity and Meth Use Disorder	active not recruiting	PHASE2	45
	NCT06700538	A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus	recruiting	PHASE1/PHASE2	180
	NCT06191848	Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)	recruiting	PHASE4	352
	NCT06662383	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity	active not recruiting	PHASE3	800
	NCT06162715	GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial	enrolling by invitation	PHASE2/PHASE3	30
	NCT06643728	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	active not recruiting	PHASE2	252
	NCT06588283	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight	active not recruiting	PHASE3	250
	NCT06588296	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight	completed	PHASE3	279
	NCT06603571	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	active not recruiting	PHASE2	350
	NCT06485089	Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers	completed	N/A	25
	NCT06565611	A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity	active not recruiting	PHASE2	108
	NCT06515418	Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over	terminated	PHASE2	204
	NCT06439277	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	recruiting	PHASE3	300
	NCT06373146	A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity	completed	PHASE2	392
	NCT06297616	A Study of LY3841136 in Japanese Participants With Obesity or Overweight	completed	PHASE1	128
	NCT06345066	A Study of LY3841136 in Overweight and Obese Participants	completed	PHASE1	96
	NCT06326060	A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight	completed	PHASE2	354
	NCT06131437	A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight	completed	PHASE3	809
	NCT06143956	A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight	recruiting	PHASE2	1,481
	NCT05912621	Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity	recruiting	PHASE2	66
	NCT06075667	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	active not recruiting	PHASE3	150
	NCT06037252	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	active not recruiting	PHASE2	414
	NCT06047548	A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	completed	PHASE3	441
	NCT07309094	Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	recruiting	N/A	250
	NCT06009653	Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity	withdrawn	PHASE4	0
	NCT05756764	Anti-obesity Pharmacotherapy and Inflammation	active not recruiting	N/A	30
	NCT05822544	Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes	recruiting	PHASE1	564
	NCT05822830	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	completed	PHASE3	751
	NCT05536804	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	active not recruiting	PHASE2	140
	NCT05696847	A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity	completed	PHASE1	28
	NCT05582096	A Study of LY3457263 in Obese Participants	completed	PHASE1	38
	NCT05556512	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	active not recruiting	PHASE3	15,374
	NCT05766358	Role Of Metabolic Adaptation In Weight Regain	completed	N/A	27
	NCT05412004	Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea	completed	PHASE3	469
	NCT05024032	A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)	completed	PHASE3	210
	NCT04844918	A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease	completed	PHASE3	267
	NCT04847557	A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial	completed	PHASE3	731
	NCT04660643	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss	completed	PHASE3	783
	NCT04657016	A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program	completed	PHASE3	579
	NCT04657003	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight	completed	PHASE3	938
	NCT04407234	A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide	completed	PHASE1	36
	NCT04311411	A Study of Tirzepatide in Overweight and Very Overweight Participants	completed	PHASE1	114
	NCT04081337	A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide	completed	PHASE1	55
	NCT04184622	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	completed	PHASE3	2,539
Overweight	NCT07438444	A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity	recruiting	PHASE4	344
	NCT07417618	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	active not recruiting	N/A	60,000
	NCT07299084	A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus	active not recruiting	PHASE1	40
	NCT06901349	A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes	withdrawn	PHASE2	0
	NCT06962280	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	active not recruiting	PHASE3	465
	NCT06965413	A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity	active not recruiting	PHASE2	285
	NCT06914895	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	active not recruiting	PHASE3	905
	NCT06916065	A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity	completed	PHASE1	188
	NCT06643728	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	active not recruiting	PHASE2	252
	NCT07096063	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	completed	N/A	887,132
	NCT06603571	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	active not recruiting	PHASE2	350
	NCT06297616	A Study of LY3841136 in Japanese Participants With Obesity or Overweight	completed	PHASE1	128
	NCT06345066	A Study of LY3841136 in Overweight and Obese Participants	completed	PHASE1	96
	NCT06143956	A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight	recruiting	PHASE2	1,481
	NCT05912621	Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity	recruiting	PHASE2	66
	NCT06075667	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	active not recruiting	PHASE3	150
	NCT06047548	A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	completed	PHASE3	441
	NCT05822830	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	completed	PHASE3	751
	NCT05536804	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	active not recruiting	PHASE2	140
	NCT05582096	A Study of LY3457263 in Obese Participants	completed	PHASE1	38
	NCT05556512	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	active not recruiting	PHASE3	15,374
	NCT05024032	A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)	completed	PHASE3	210
	NCT04660643	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss	completed	PHASE3	783
	NCT04657016	A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program	completed	PHASE3	579
	NCT04657003	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight	completed	PHASE3	938
	NCT04407234	A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide	completed	PHASE1	36
	NCT04311411	A Study of Tirzepatide in Overweight and Very Overweight Participants	completed	PHASE1	114
	NCT04184622	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	completed	PHASE3	2,539
Type 2 Diabetes	NCT07417618	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	active not recruiting	N/A	60,000
	NCT06657209	Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide	recruiting	PHASE4	104
	NCT06980623	Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction	active not recruiting	N/A	26,000
	NCT06779929	Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	completed	N/A	70,000
	NCT06635057	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan	completed	PHASE4	166
	NCT07096063	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	completed	N/A	887,132
	NCT07088718	Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data	completed	N/A	44,671
	NCT06221969	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	completed	PHASE3	1,024
	NCT06037252	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	active not recruiting	PHASE2	414
	NCT05963022	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)	completed	PHASE3	206
	NCT05822544	Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes	recruiting	PHASE1	564
	NCT05706506	A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)	completed	PHASE4	152
	NCT05536804	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	active not recruiting	PHASE2	140
	NCT05564039	A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)	completed	PHASE4	282
	NCT05433584	A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes	active not recruiting	PHASE4	780
	NCT04657003	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight	completed	PHASE3	938
	NCT04537923	A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin	completed	PHASE3	1,428
	NCT04093752	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)	completed	PHASE3	917
	NCT04039503	A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin	completed	PHASE3	475
	NCT03987919	A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes	completed	PHASE3	1,879
	NCT03861052	A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes	completed	PHASE3	636
	NCT03311724	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes	completed	PHASE2	111
Diabetes Mellitus, Type 2	NCT07438444	A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity	recruiting	PHASE4	344
	NCT07299084	A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus	active not recruiting	PHASE1	40
	NCT06914154	Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data	completed	N/A	11,265
	NCT06914141	Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction	completed	N/A	28,118
	NCT06657209	Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide	recruiting	PHASE4	104
	NCT06534411	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both	active not recruiting	PHASE3	1,023
	NCT07309094	Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	recruiting	N/A	250
	NCT05706506	A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)	completed	PHASE4	152
	NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	completed	PHASE3	99
	NCT04235959	A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus	completed	PHASE1	24
	NCT04407234	A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide	completed	PHASE1	36
	NCT04050553	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus	completed	PHASE1	42
	NCT03951753	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)	completed	PHASE1	117
Healthy	NCT06890611	A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants	completed	PHASE1	125
	NCT05978713	A Study of Tirzepatide (LY3298176) in Healthy Lactating Females	completed	PHASE1	11
	NCT05810597	A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices	completed	PHASE1	65
	NCT04311424	Study of Tirzepatide in Healthy Participants	completed	PHASE1	6
	NCT04172987	A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants	completed	PHASE1	40
	NCT04050670	A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes	completed	PHASE1	54
	NCT04004988	A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants	completed	PHASE1	47
	NCT03375463	A Study of Tirzepatide (LY3298176) in Healthy Participants	completed	PHASE1	52
	NCT02759107	A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)	completed	PHASE1	142
Type 2 Diabetes Mellitus	NCT07492563	Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay	not yet recruiting	N/A	300
	NCT05553093	Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes	recruiting	PHASE4	150
	NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	completed	PHASE3	13,299
	NCT03954834	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone	completed	PHASE3	478
	NCT03882970	A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes	completed	PHASE3	1,444
	NCT03861039	A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes	completed	PHASE3	443
	NCT03730662	A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk	completed	PHASE3	2,002
	NCT03322631	A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes	completed	PHASE1	48
	NCT03131687	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus	completed	PHASE2	318
Obesity & Overweight	NCT07298915	The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)	not yet recruiting	PHASE3	24
	NCT07382024	Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation	not yet recruiting	NA	200
	NCT07443956	Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis	recruiting	NA	45
	NCT07364175	A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults	recruiting	NA	60
	NCT07326111	A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese	recruiting	PHASE4	198
	NCT07382180	Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients	completed	N/A	254
Obesity and Overweight	NCT06732245	Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese	not yet recruiting	PHASE2	224
	NCT06935838	Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV	recruiting	PHASE2	12
	NCT06994338	Tirzepatide for Alcohol Use Disorder	recruiting	PHASE2	42
	NCT06847399	Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder	recruiting	PHASE2	105
	NCT06737042	Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants	not yet recruiting	PHASE2	285
Obesity (Disorder)	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
	NCT07257484	Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors	not yet recruiting	PHASE4	30
	NCT07504172	Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity	not yet recruiting	N/A	1,700
	NCT07373834	Tirzepatide and Muscle Outcomes in Obesity	recruiting	NA	30
Alcohol Use Disorder	NCT07046819	Tirzepatide in MetALD	recruiting	PHASE2	120
	NCT06994338	Tirzepatide for Alcohol Use Disorder	recruiting	PHASE2	42
	NCT06939088	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	recruiting	PHASE2	108
Overweight and Obesity	NCT06180616	Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity	not yet recruiting	PHASE2	40
	NCT06445075	Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese	completed	PHASE2	102
	NCT05912621	Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity	recruiting	PHASE2	66
Metabolic Disease	NCT06009653	Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity	withdrawn	PHASE4	0
	NCT05691712	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	completed	PHASE3	257
	NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	completed	PHASE3	99
Diabetes	NCT06759701	Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study	recruiting	EARLY_PHASE1	30
	NCT06657209	Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide	recruiting	PHASE4	104
	NCT05990374	Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years	unknown	NA	100
Type 1 Diabetes	NCT07284511	A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar	recruiting	PHASE2/PHASE3	105
	NCT06962280	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	active not recruiting	PHASE3	465
	NCT06914895	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	active not recruiting	PHASE3	905
Psoriatic Arthritis	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
	NCT06864026	A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)	recruiting	PHASE4	200
	NCT06588296	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight	completed	PHASE3	279
Type 1 Diabetes Mellitus	NCT06180616	Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity	not yet recruiting	PHASE2	40
	NCT07284511	A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar	recruiting	PHASE2/PHASE3	105
	NCT06820281	Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes	not yet recruiting	PHASE2	44
Endometrial Cancer	NCT07078838	Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer	not yet recruiting	PHASE2	40
	NCT07065552	Tirzepatide in Obesity-Driven Endometrial Cancer	recruiting	EARLY_PHASE1	20
	NCT06751589	A Study of a Weight Loss Intervention in People With Endometrial Cancer	recruiting	EARLY_PHASE1	36
Heart Failure	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
	NCT06980623	Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction	active not recruiting	N/A	26,000
	NCT07303556	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs	active not recruiting	NA	120
Obesity and Obesity-related Medical Conditions	NCT06721507	2024 Tirzepatide-Bariatric Surgery	recruiting	PHASE4	50
	NCT06803888	Bariatric Surgery vs. Semaglutide vs. Tirzepatide	active not recruiting	PHASE4	125
	NCT06918405	Efficacy and Safety of Tirzepatide for Weight Management	active not recruiting	PHASE3	440
Overweight or Obesity	NCT06857942	A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)	recruiting	PHASE4	200
	NCT06864026	A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)	recruiting	PHASE4	200
	NCT06606821	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease	recruiting	PHASE4	124
Alcohol Use Disorder (AUD)	NCT07559500	Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)	recruiting	PHASE1	176
	NCT07292519	Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)	not yet recruiting	PHASE2	46
	NCT06727331	Study of Tirzepatide for Recovery and Alcohol Use Management	recruiting	PHASE2	20
Cardiovascular (CV) Risk	NCT07096063	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	completed	N/A	887,132
	NCT07088718	Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data	completed	N/A	44,671
Cannabis Use Disorder	NCT07468552	Trial of Tirzepatide for the Treatment of Cannabis Use Disorder	not yet recruiting	PHASE2	100
	NCT07265752	Tirzepatide for the Treatment of Cannabis Use Disorder	not yet recruiting	PHASE2	6
T2D	NCT05536804	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	active not recruiting	PHASE2	140
	NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	completed	PHASE3	99
Breast Cancer	NCT07257484	Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors	not yet recruiting	PHASE4	30
	NCT06517212	Tirzepatide Weight Loss for MRD+ Early Breast Cancer	recruiting	PHASE2	48
Type 2 Diabetes Mellitus (T2DM)	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
	NCT02759107	A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)	completed	PHASE1	142
Obesity or Overweight	NCT06937099	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight	recruiting	PHASE3	290
	NCT06937086	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study	recruiting	PHASE3	350
Coronary Artery Disease	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
	NCT06606821	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease	recruiting	PHASE4	124
Glucose Metabolism Disorders	NCT05691712	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	completed	PHASE3	257
	NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	completed	PHASE3	99
Psoriasis	NCT06857942	A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)	recruiting	PHASE4	200
	NCT06588283	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight	active not recruiting	PHASE3	250
Weight Gain	NCT06439277	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	recruiting	PHASE3	300
	NCT05766358	Role Of Metabolic Adaptation In Weight Regain	completed	N/A	27
Weight Loss	NCT06811324	Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults	recruiting	PHASE2	20
	NCT05766358	Role Of Metabolic Adaptation In Weight Regain	completed	N/A	27
Diabetes Mellitus	NCT05691712	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	completed	PHASE3	257
	NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	completed	PHASE3	99
Endocrine System Diseases	NCT05691712	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	completed	PHASE3	257
	NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	completed	PHASE3	99
Coronary Microvascular Dysfunction	NCT06606821	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease	recruiting	PHASE4	124
Crohn's Disease	NCT06937099	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight	recruiting	PHASE3	290
Crohn Disease	NCT06774079	Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients	recruiting	PHASE4	24
Crohn Disease (CD)	NCT06976853	Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease	recruiting	PHASE2	60
Diabete Type 2	NCT07303556	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs	active not recruiting	NA	120
Diabetes (DM)	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Diabetes Type 2	NCT05691712	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	completed	PHASE3	257
Drug Effect	NCT07154719	GLP-1R Actions on Muscle and the Skeleton	recruiting	PHASE4	50
End Stage Renal Disease	NCT03482024	A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function	completed	PHASE1	45
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia	NCT07349641	A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer	not yet recruiting	PHASE2	55
Endometrial Intraepithelial Neoplasia	NCT07078838	Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer	not yet recruiting	PHASE2	40
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	NCT07349641	A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer	not yet recruiting	PHASE2	55
GLP - 1	NCT06811324	Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults	recruiting	PHASE2	20
Grade 1 Endometrial Endometrioid Carcinoma	NCT07078838	Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer	not yet recruiting	PHASE2	40
Healthy Subjects	NCT05822544	Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes	recruiting	PHASE1	564
Heart Failure With Preserved Ejection Fraction	NCT07554638	Incretin Therapies in Obesity-related HFpEF	not yet recruiting	PHASE4	50
Heart Failure With Preserved Ejection Fraction (HFpEF)	NCT06914154	Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data	completed	N/A	11,265
	NCT04847557	A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial	completed	PHASE3	731
Heart Failure With Preserved Ejection Fraction (HFPEF)	NCT06914154	Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data	completed	N/A	11,265
	NCT04847557	A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial	completed	PHASE3	731
Heart Failure, Diastolic	NCT07554638	Incretin Therapies in Obesity-related HFpEF	not yet recruiting	PHASE4	50
Hepatic Insufficiency	NCT03940742	A Study of Tirzepatide in Participants With Impaired Liver Function	completed	PHASE1	32
HER2-Negative Breast Cancer	NCT06518837	Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer	recruiting	PHASE2	40
HFpEF - Heart Failure With Preserved Ejection Fraction	NCT06914141	Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction	completed	N/A	28,118
Hidradenitis Suppurativa	NCT06301256	Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa	unknown	NA	20
HIV	NCT06935838	Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV	recruiting	PHASE2	12
Hormone Receptor-Positive Breast Cancer	NCT06518837	Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer	recruiting	PHASE2	40
Hypertension	NCT07364175	A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults	recruiting	NA	60
Hypoglycemia	NCT04050553	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus	completed	PHASE1	42
Hypothalamic Obesity	NCT06901245	Tirzepatide in PWS, HO and GNSO	recruiting	PHASE4	36
Idiopathic Intracranial Hypertension (IIH)	NCT07191873	Tirzepatide in Idiopathic Intracranial Hypertension Trial	not yet recruiting	PHASE4	60
Insulin Resistance Syndrome	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Knee	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Knee Osteoarthritis	NCT06191848	Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)	recruiting	PHASE4	352
Lipodystrophy, Partial	NCT07091734	Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024	recruiting	PHASE2	32
Long COVID	NCT07128082	The Long COVID Treatment Trial	active not recruiting	PHASE2	1,000
Major Adverse Cardiac Events	NCT07088718	Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data	completed	N/A	44,671
MASLD	NCT06934642	Effect of Tirzepatide on Markers of MASLD in Patients With Obesity	recruiting	EARLY_PHASE1	8
Menopause	NCT07057310	Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	enrolling by invitation	PHASE4	30
Menopause Hot Flashes	NCT07218445	The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity	recruiting	PHASE4	40
Metabolic Alcohol-associated Liver Disease	NCT07046819	Tirzepatide in MetALD	recruiting	PHASE2	120
Metabolic Dysfunction-Associated Steatotic Liver Disease	NCT07165028	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	recruiting	PHASE3	4,500
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	NCT07527910	A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD	not yet recruiting	PHASE2	204
Metabolic Health	NCT06354101	The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.	withdrawn	N/A	0
Metabolic Syndrome	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Metabolism and Nutrition Disorder	NCT05024032	A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)	completed	PHASE3	210
Methamphetamine Use Disorder	NCT06745128	Tirzepatide for Obesity and Meth Use Disorder	active not recruiting	PHASE2	45
Mild Autonomous Cortisol Secretion (MACS)	NCT07573163	Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion	not yet recruiting	PHASE2	34
Musculoskeletal Abnormalities	NCT07154719	GLP-1R Actions on Muscle and the Skeleton	recruiting	PHASE4	50
Non Alcholic Fatty Liver Disease	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Nonalcoholic Steatohepatitis	NCT04166773	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)	completed	PHASE2	190
Obesity-related Male Infertility	NCT07179120	Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health	not yet recruiting	PHASE2	180
Obesity &Amp; Overweight	NCT07245771	Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity	recruiting	PHASE1/PHASE2	104
Obesity Prevention	NCT06811324	Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults	recruiting	PHASE2	20
Obesity, Morbid	NCT07382180	Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients	completed	N/A	254
Obesity/Therapy	NCT06901245	Tirzepatide in PWS, HO and GNSO	recruiting	PHASE4	36
Obstructive Sleep Apnea	NCT05412004	Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea	completed	PHASE3	469
Opioid Use Disorder	NCT06651177	Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder	recruiting	PHASE2	310
Opioid Use Disorder, Moderate	NCT06651177	Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder	recruiting	PHASE2	310
Opioid Use Disorder, Severe	NCT06651177	Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder	recruiting	PHASE2	310
Osteoarthitis	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Osteoarthritis, Knee	NCT06191848	Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)	recruiting	PHASE4	352
Osteoporosis	NCT07154719	GLP-1R Actions on Muscle and the Skeleton	recruiting	PHASE4	50
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities	NCT07481747	Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)	recruiting	PHASE3	2,539
Overweight , Obesity	NCT07504172	Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity	not yet recruiting	N/A	1,700
Overweight or Obese	NCT07292519	Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)	not yet recruiting	PHASE2	46
Overweight or Obesity; Type 2 Diabetes	NCT07555730	AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)	not yet recruiting	PHASE4	400
Overweight With Comorbidities	NCT07492563	Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay	not yet recruiting	N/A	300
Overweight With One Weight Related Comorbidity	NCT06965413	A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity	active not recruiting	PHASE2	285
Pericardium	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Persistent Atrial Fibrillation	NCT07382024	Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation	not yet recruiting	NA	200
Polycystic Ovary Syndrome (PCOS)	NCT07326111	A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese	recruiting	PHASE4	198
Prader-Willi Syndrome	NCT06901245	Tirzepatide in PWS, HO and GNSO	recruiting	PHASE4	36
Pre Diabetes	NCT06657209	Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide	recruiting	PHASE4	104
Preserved Ejection Fraction	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Prostate Cancer	NCT06759701	Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study	recruiting	EARLY_PHASE1	30
Prostate Carcinoma	NCT07202247	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	recruiting	PHASE2	60
Psoriatic Arthritis (PsA)	NCT07443956	Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis	recruiting	NA	45
Recurrent Prostate Carcinoma	NCT07202247	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	recruiting	PHASE2	60
Renal Insufficiency	NCT03482024	A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function	completed	PHASE1	45
Sarcopenia	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Sarcopenia in Elderly	NCT06811324	Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults	recruiting	PHASE2	20
Sarcopenic Obesity	NCT07154719	GLP-1R Actions on Muscle and the Skeleton	recruiting	PHASE4	50
Schizophrenia	NCT06939088	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	recruiting	PHASE2	108
Schizophrenia and Disorders With Psychotic Features	NCT06939088	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	recruiting	PHASE2	108
Schizophrenia and Schizophrenia Spectrum Psychosis	NCT06939088	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	recruiting	PHASE2	108
Schizophrenia Disorders	NCT06939088	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	recruiting	PHASE2	108
Severe Obesity	NCT06162715	GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial	enrolling by invitation	PHASE2/PHASE3	30
Stable Angina Pectoris	NCT06606821	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease	recruiting	PHASE4	124
T1D	NCT07284511	A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar	recruiting	PHASE2/PHASE3	105
T1DM	NCT07284511	A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar	recruiting	PHASE2/PHASE3	105
T1DM - Type 1 Diabetes Mellitus	NCT07284511	A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar	recruiting	PHASE2/PHASE3	105
T2DM (Type 2 Diabetes Mellitus)	NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	completed	PHASE3	99
Tirzepatide	NCT07423247	Tirzepatide (Spartina) in Obese Kidney Transplant Recipients	recruiting	PHASE4	30
Type 1 Diabetes (T1D)	NCT06630585	GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes	recruiting	PHASE3	42
Type 2 Diabetes (Adult Onset)	NCT06246799	Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes	recruiting	PHASE3	256
Type II Diabetes	NCT05708859	Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT	recruiting	PHASE4	120
Type1diabetes	NCT07096908	Tirzepatide Use in People With Obesity and Type 1 Diabetes	recruiting	PHASE4	60
Type2 Diabetes	NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	completed	PHASE3	99
Type2 Diabetes Mellitus	NCT07203677	Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)	completed	N/A	49,065
Type2diabetes	NCT06648031	Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants	completed	PHASE1	148
Ulcerative Colitis	NCT06937086	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study	recruiting	PHASE3	350
Weight Loss Maintenance	NCT07555730	AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)	not yet recruiting	PHASE4	400
Weight Regain	NCT07382180	Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients	completed	N/A	254
Acute Lymphoblastic Leukemia	NCT07228741	Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity	recruiting	PHASE2	20
Wolfram Syndrome	NCT05659368	Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1	unknown	PHASE2	10
Adrenalectomy; Status	NCT07573163	Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion	not yet recruiting	PHASE2	34
Adults With Simple Obesity	NCT07293325	Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity	recruiting	NA	66
Alcohol	NCT06994338	Tirzepatide for Alcohol Use Disorder	recruiting	PHASE2	42
Alcohol Abuse/Dependence	NCT06939088	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	recruiting	PHASE2	108
Alcohol Dependence	NCT06939088	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	recruiting	PHASE2	108
Alcoholism	NCT06939088	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	recruiting	PHASE2	108
Arterial Hypertension	NCT07303556	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs	active not recruiting	NA	120
ASCVD	NCT07417618	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	active not recruiting	N/A	60,000
Atherosclerosis	NCT05708859	Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT	recruiting	PHASE4	120
Atherosclerosis Cardiovascular Disease	NCT06606821	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease	recruiting	PHASE4	124
Atherosclerotic Cardiovascular Disease	NCT07203677	Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)	completed	N/A	49,065
Atrial Fibrillation	NCT06802081	TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation	recruiting	PHASE2	100
Atrial Fibrillation (AF)	NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30
Atrial Fibrillation Ablation	NCT07382024	Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation	not yet recruiting	NA	200
Autosomal Dominant Polycystic Kidney	NCT06582875	Glucagon-Like Peptide-1 Receptor Agonist in ADPKD	recruiting	PHASE2	126
Bariatric Surgery	NCT06721507	2024 Tirzepatide-Bariatric Surgery	recruiting	PHASE4	50
Binge Eating Disorder	NCT06847399	Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder	recruiting	PHASE2	105
BMI Greater Than 30	NCT06162715	GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial	enrolling by invitation	PHASE2/PHASE3	30
Breast Cancer Risk	NCT06485089	Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers	completed	N/A	25
Breast Cancers	NCT06517212	Tirzepatide Weight Loss for MRD+ Early Breast Cancer	recruiting	PHASE2	48
Breast Neoplasms	NCT06517212	Tirzepatide Weight Loss for MRD+ Early Breast Cancer	recruiting	PHASE2	48
Cardiovascular Diseases	NCT07483801	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies	not yet recruiting	PHASE4	112
Cardiovascular Function	NCT06811324	Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults	recruiting	PHASE2	20
Chronic Coronary Artery Disease	NCT06606821	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease	recruiting	PHASE4	124
Chronic Inflammation	NCT06935838	Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV	recruiting	PHASE2	12
Chronic Kidney Disease	NCT05536804	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	active not recruiting	PHASE2	140
Chronic Kidney Disease Stage 1	NCT07309094	Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	recruiting	N/A	250
Chronic Kidney Disease Stage 2	NCT07309094	Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	recruiting	N/A	250
Chronic Kidney Disease stage3	NCT07309094	Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	recruiting	N/A	250
Chronic Kidney Disease stage4	NCT07309094	Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	recruiting	N/A	250
Colorectal Adenoma	NCT07095517	Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors	recruiting	PHASE1	20
Colorectal Cancer Prevention	NCT07095517	Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors	recruiting	PHASE1	20
Comorbidities and Coexisting Conditions	NCT07292519	Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)	not yet recruiting	PHASE2	46

All Tirzepatide Clinical Trials (190)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT06180616	Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity	not yet recruiting	PHASE2	40	Royal North Shore Hospital
NCT07468552	Trial of Tirzepatide for the Treatment of Cannabis Use Disorder	not yet recruiting	PHASE2	100	National Institute on Drug Abuse (NIDA)
NCT07298915	The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)	not yet recruiting	PHASE3	24	University of Virginia
NCT06732245	Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese	not yet recruiting	PHASE2	224	Biomed Industries, Inc.
NCT07573163	Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion	not yet recruiting	PHASE2	34	Alaa Sada
NCT07349641	A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer	not yet recruiting	PHASE2	55	National Cancer Institute (NCI)
NCT07265752	Tirzepatide for the Treatment of Cannabis Use Disorder	not yet recruiting	PHASE2	6	Brigham and Women's Hospital
NCT07554638	Incretin Therapies in Obesity-related HFpEF	not yet recruiting	PHASE4	50	Columbia University
NCT07567378	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	not yet recruiting	N/A	30	JULIO GRANADOS MONTIEL
NCT07559500	Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)	recruiting	PHASE1	176	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NCT07382024	Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation	not yet recruiting	NA	200	National Taiwan University Hospital
NCT07179120	Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health	not yet recruiting	PHASE2	180	First Affiliated Hospital of Wenzhou Medical University
NCT07218445	The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity	recruiting	PHASE4	40	Mayo Clinic
NCT07078838	Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer	not yet recruiting	PHASE2	40	UNC Lineberger Comprehensive Cancer Center
NCT07555730	AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)	not yet recruiting	PHASE4	400	Huazhong University of Science and Technology
NCT07065552	Tirzepatide in Obesity-Driven Endometrial Cancer	recruiting	EARLY_PHASE1	20	UNC Lineberger Comprehensive Cancer Center
NCT07228741	Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity	recruiting	PHASE2	20	St. Jude Children's Research Hospital
NCT07527910	A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD	not yet recruiting	PHASE2	204	Regeneron Pharmaceuticals
NCT07257484	Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors	not yet recruiting	PHASE4	30	Weill Medical College of Cornell University
NCT06811324	Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults	recruiting	PHASE2	20	The University of Texas Health Science Center at San Antonio
NCT07504172	Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity	not yet recruiting	N/A	1,700	Radboud University Medical Center
NCT07046819	Tirzepatide in MetALD	recruiting	PHASE2	120	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NCT07483801	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies	not yet recruiting	PHASE4	112	Cambridge University Hospitals NHS Foundation Trust
NCT07492563	Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay	not yet recruiting	N/A	300	LABORATORIOS INDUFAR
NCT07521631	Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes	recruiting	PHASE2	372	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT07443956	Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis	recruiting	NA	45	NHS Greater Glasgow and Clyde
NCT07463846	A Study to Evaluate ALN-2232 in Participants With Obesity	recruiting	PHASE1/PHASE2	156	Alnylam Pharmaceuticals
NCT07191873	Tirzepatide in Idiopathic Intracranial Hypertension Trial	not yet recruiting	PHASE4	60	Duke University
NCT07438444	A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity	recruiting	PHASE4	344	Eli Lilly and Company
NCT07095517	Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors	recruiting	PHASE1	20	Massachusetts General Hospital
NCT07481747	Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)	recruiting	PHASE3	2,539	Hudson Biotech
NCT07176663	Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure	not yet recruiting	NA	15	Shahid Beheshti University of Medical Sciences
NCT07373834	Tirzepatide and Muscle Outcomes in Obesity	recruiting	NA	30	University Medical Centre Ljubljana
NCT07364175	A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults	recruiting	NA	60	Cambridge University Hospitals NHS Foundation Trust
NCT06651177	Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder	recruiting	PHASE2	310	T. John Winhusen, PhD
NCT07417618	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	active not recruiting	N/A	60,000	Brigham and Women's Hospital
NCT07202247	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	recruiting	PHASE2	60	City of Hope Medical Center
NCT07292519	Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)	not yet recruiting	PHASE2	46	South West Sydney Local Health District
NCT07299084	A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus	active not recruiting	PHASE1	40	Eli Lilly and Company
NCT07284511	A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar	recruiting	PHASE2/PHASE3	105	McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT07423247	Tirzepatide (Spartina) in Obese Kidney Transplant Recipients	recruiting	PHASE4	30	Shahid Beheshti University of Medical Sciences
NCT07319975	Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity	not yet recruiting	NA	48	Istanbul Galata University
NCT07326111	A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese	recruiting	PHASE4	198	University of Bonn
NCT06820281	Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes	not yet recruiting	PHASE2	44	Victor Chang Cardiac Research Institute
NCT07247084	A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)	recruiting	PHASE4	3,000	Eli Lilly and Company
NCT06935838	Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV	recruiting	PHASE2	12	University of Hawaii
NCT05933499	Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity	recruiting	PHASE2	63	Massachusetts General Hospital
NCT07245771	Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity	recruiting	PHASE1/PHASE2	104	Ikaria Bioscience Pty Ltd
NCT07128082	The Long COVID Treatment Trial	active not recruiting	PHASE2	1,000	Scripps Translational Science Institute
NCT07165028	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	recruiting	PHASE3	4,500	Eli Lilly and Company
NCT07154719	GLP-1R Actions on Muscle and the Skeleton	recruiting	PHASE4	50	Pennington Biomedical Research Center
NCT06994338	Tirzepatide for Alcohol Use Disorder	recruiting	PHASE2	42	University of Southern California
NCT06801015	Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions	active not recruiting	PHASE4	30	Mayo Clinic
NCT07099742	Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)	not yet recruiting	N/A	364	Dr. Md. Alimur Reza
NCT07203677	Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)	completed	N/A	49,065	Brigham and Women's Hospital
NCT06847399	Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder	recruiting	PHASE2	105	Johns Hopkins University
NCT06727331	Study of Tirzepatide for Recovery and Alcohol Use Management	recruiting	PHASE2	20	Brigham and Women's Hospital
NCT07091734	Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024	recruiting	PHASE2	32	University of Michigan
NCT07096908	Tirzepatide Use in People With Obesity and Type 1 Diabetes	recruiting	PHASE4	60	Dasman Diabetes Institute
NCT06861439	GLP-1s to Enhance Lasting Optimal Weight	active not recruiting	PHASE4	40	Wake Forest University Health Sciences
NCT06759701	Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study	recruiting	EARLY_PHASE1	30	M.D. Anderson Cancer Center
NCT06934642	Effect of Tirzepatide on Markers of MASLD in Patients With Obesity	recruiting	EARLY_PHASE1	8	University of New Mexico
NCT06937099	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight	recruiting	PHASE3	290	Eli Lilly and Company
NCT06937086	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study	recruiting	PHASE3	350	Eli Lilly and Company
NCT07000955	Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity	active not recruiting	PHASE1/PHASE2	98	Innovent Biologics (Suzhou) Co. Ltd.
NCT07293325	Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity	recruiting	NA	66	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06901349	A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes	withdrawn	PHASE2	0	Eli Lilly and Company
NCT06976853	Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease	recruiting	PHASE2	60	Washington University School of Medicine
NCT06962280	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	active not recruiting	PHASE3	465	Eli Lilly and Company
NCT06965413	A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity	active not recruiting	PHASE2	285	Hoffmann-La Roche
NCT06939088	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	recruiting	PHASE2	108	Anders Fink-Jensen, MD, DMSci
NCT07057310	Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	enrolling by invitation	PHASE4	30	Mayo Clinic
NCT06901245	Tirzepatide in PWS, HO and GNSO	recruiting	PHASE4	36	Grace Kim
NCT06914895	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	active not recruiting	PHASE3	905	Eli Lilly and Company
NCT06916065	A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity	completed	PHASE1	188	Eli Lilly and Company
NCT06802081	TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation	recruiting	PHASE2	100	The Cleveland Clinic
NCT06911203	A Study of BGM0504 in Participants With Obesity	recruiting	PHASE2	90	BrightGene Bio-Medical Technology Co., Ltd.
NCT06721507	2024 Tirzepatide-Bariatric Surgery	recruiting	PHASE4	50	Marlene Starr
NCT06890611	A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants	completed	PHASE1	125	Eli Lilly and Company
NCT06857942	A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)	recruiting	PHASE4	200	Eli Lilly and Company
NCT06893211	Effect of Tirzepatide on Brown Adipose Tissue in Obesity	active not recruiting	PHASE2	35	University Medical Centre Ljubljana
NCT06582875	Glucagon-Like Peptide-1 Receptor Agonist in ADPKD	recruiting	PHASE2	126	University of Colorado, Denver
NCT06864026	A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)	recruiting	PHASE4	200	Eli Lilly and Company
NCT06774079	Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients	recruiting	PHASE4	24	University of Miami
NCT06630585	GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes	recruiting	PHASE3	42	University of Bern
NCT06737042	Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants	not yet recruiting	PHASE2	285	Gan and Lee Pharmaceuticals, USA
NCT06745128	Tirzepatide for Obesity and Meth Use Disorder	active not recruiting	PHASE2	45	University of Texas Southwestern Medical Center
NCT07382180	Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients	completed	N/A	254	Azienda Sanitaria Locale Napoli 2 Nord
NCT06803888	Bariatric Surgery vs. Semaglutide vs. Tirzepatide	active not recruiting	PHASE4	125	Ali Aminian
NCT06914154	Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data	completed	N/A	11,265	Brigham and Women's Hospital
NCT06914141	Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction	completed	N/A	28,118	Brigham and Women's Hospital
NCT06657209	Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide	recruiting	PHASE4	104	Stanford University
NCT06918405	Efficacy and Safety of Tirzepatide for Weight Management	active not recruiting	PHASE3	440	Chittagong Medical College
NCT06980623	Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction	active not recruiting	N/A	26,000	Brigham and Women's Hospital
NCT06751589	A Study of a Weight Loss Intervention in People With Endometrial Cancer	recruiting	EARLY_PHASE1	36	Memorial Sloan Kettering Cancer Center
NCT07303556	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs	active not recruiting	NA	120	Nazarbayev University
NCT06700538	A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus	recruiting	PHASE1/PHASE2	180	Arrowhead Pharmaceuticals
NCT06648031	Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants	completed	PHASE1	148	Lexaria Bioscience Corp.
NCT06517212	Tirzepatide Weight Loss for MRD+ Early Breast Cancer	recruiting	PHASE2	48	Baylor Research Institute
NCT06191848	Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)	recruiting	PHASE4	352	University of Melbourne
NCT06246799	Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes	recruiting	PHASE3	256	The University of Texas Health Science Center at San Antonio
NCT06534411	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both	active not recruiting	PHASE3	1,023	Novo Nordisk A/S
NCT06662383	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity	active not recruiting	PHASE3	800	Eli Lilly and Company
NCT06779929	Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	completed	N/A	70,000	Brigham and Women's Hospital
NCT06518837	Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer	recruiting	PHASE2	40	Rutgers, The State University of New Jersey
NCT06162715	GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial	enrolling by invitation	PHASE2/PHASE3	30	Vanderbilt University Medical Center
NCT06643728	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	active not recruiting	PHASE2	252	Eli Lilly and Company
NCT06635057	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan	completed	PHASE4	166	Eli Lilly and Company
NCT07096063	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	completed	N/A	887,132	Brigham and Women's Hospital
NCT06606821	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease	recruiting	PHASE4	124	Tina Vilsbøll
NCT07088718	Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data	completed	N/A	44,671	Brigham and Women's Hospital
NCT06588283	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight	active not recruiting	PHASE3	250	Eli Lilly and Company
NCT06588296	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight	completed	PHASE3	279	Eli Lilly and Company
NCT06603571	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	active not recruiting	PHASE2	350	Eli Lilly and Company
NCT06485089	Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers	completed	N/A	25	University of Kansas Medical Center
NCT06565611	A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity	active not recruiting	PHASE2	108	Palatin Technologies, Inc
NCT06515418	Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over	terminated	PHASE2	204	BioAge Labs, Inc.
NCT06439277	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	recruiting	PHASE3	300	Eli Lilly and Company
NCT06445075	Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese	completed	PHASE2	102	Scholar Rock, Inc.
NCT06373146	A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity	completed	PHASE2	392	Eli Lilly and Company
NCT06297616	A Study of LY3841136 in Japanese Participants With Obesity or Overweight	completed	PHASE1	128	Eli Lilly and Company
NCT06345066	A Study of LY3841136 in Overweight and Obese Participants	completed	PHASE1	96	Eli Lilly and Company
NCT06326060	A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight	completed	PHASE2	354	Novo Nordisk A/S
NCT06301256	Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa	unknown	NA	20	Florida Academic Centers Research and Education, LLC
NCT06221969	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	completed	PHASE3	1,024	Novo Nordisk A/S
NCT05708859	Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT	recruiting	PHASE4	120	Matthew J. Budoff
NCT05659368	Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1	unknown	PHASE2	10	Ospedale San Raffaele
NCT06131437	A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight	completed	PHASE3	809	Novo Nordisk A/S
NCT06143956	A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight	recruiting	PHASE2	1,481	Eli Lilly and Company
NCT05912621	Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity	recruiting	PHASE2	66	Stanford University
NCT06075667	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	active not recruiting	PHASE3	150	Eli Lilly and Company
NCT06037252	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	active not recruiting	PHASE2	414	Eli Lilly and Company
NCT06047548	A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	completed	PHASE3	441	Eli Lilly and Company
NCT07309094	Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	recruiting	N/A	250	Cardenal Herrera University
NCT06009653	Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity	withdrawn	PHASE4	0	Washington University School of Medicine
NCT05963022	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)	completed	PHASE3	206	Eli Lilly and Company
NCT05990374	Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years	unknown	NA	100	Nanjing First Hospital, Nanjing Medical University
NCT05978713	A Study of Tirzepatide (LY3298176) in Healthy Lactating Females	completed	PHASE1	11	Eli Lilly and Company
NCT06354101	The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.	withdrawn	N/A	0	CorEvitas
NCT05756764	Anti-obesity Pharmacotherapy and Inflammation	active not recruiting	N/A	30	Louisiana State University Health Sciences Center in New Orleans
NCT05822544	Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes	recruiting	PHASE1	564	OrsoBio, Inc
NCT05822830	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	completed	PHASE3	751	Eli Lilly and Company
NCT05810597	A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices	completed	PHASE1	65	Eli Lilly and Company
NCT05706506	A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)	completed	PHASE4	152	Eli Lilly and Company
NCT05536804	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	active not recruiting	PHASE2	140	Eli Lilly and Company
NCT05696847	A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity	completed	PHASE1	28	Eli Lilly and Company
NCT05691712	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	completed	PHASE3	257	Eli Lilly and Company
NCT05564039	A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)	completed	PHASE4	282	Eli Lilly and Company
NCT05582096	A Study of LY3457263 in Obese Participants	completed	PHASE1	38	Eli Lilly and Company
NCT05556512	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	active not recruiting	PHASE3	15,374	Eli Lilly and Company
NCT05766358	Role Of Metabolic Adaptation In Weight Regain	completed	N/A	27	Pennington Biomedical Research Center
NCT05433584	A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes	active not recruiting	PHASE4	780	Eli Lilly and Company
NCT05412004	Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea	completed	PHASE3	469	Eli Lilly and Company
NCT05260021	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	completed	PHASE3	99	Eli Lilly and Company
NCT05553093	Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes	recruiting	PHASE4	150	Nanjing First Hospital, Nanjing Medical University
NCT05024032	A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)	completed	PHASE3	210	Eli Lilly and Company
NCT04844918	A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease	completed	PHASE3	267	Eli Lilly and Company
NCT04847557	A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial	completed	PHASE3	731	Eli Lilly and Company
NCT04660643	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss	completed	PHASE3	783	Eli Lilly and Company
NCT04657016	A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program	completed	PHASE3	579	Eli Lilly and Company
NCT04657003	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight	completed	PHASE3	938	Eli Lilly and Company
NCT04235959	A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus	completed	PHASE1	24	Eli Lilly and Company
NCT04537923	A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin	completed	PHASE3	1,428	Eli Lilly and Company
NCT04407234	A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide	completed	PHASE1	36	Eli Lilly and Company
NCT04311411	A Study of Tirzepatide in Overweight and Very Overweight Participants	completed	PHASE1	114	Eli Lilly and Company
NCT04311424	Study of Tirzepatide in Healthy Participants	completed	PHASE1	6	Eli Lilly and Company
NCT04081337	A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide	completed	PHASE1	55	Eli Lilly and Company
NCT04255433	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	completed	PHASE3	13,299	Eli Lilly and Company
NCT04172987	A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants	completed	PHASE1	40	Eli Lilly and Company
NCT04050553	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus	completed	PHASE1	42	Eli Lilly and Company
NCT04093752	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)	completed	PHASE3	917	Eli Lilly and Company
NCT04184622	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	completed	PHASE3	2,539	Eli Lilly and Company
NCT04166773	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)	completed	PHASE2	190	Eli Lilly and Company
NCT04050670	A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes	completed	PHASE1	54	Eli Lilly and Company
NCT04039503	A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin	completed	PHASE3	475	Eli Lilly and Company
NCT04004988	A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants	completed	PHASE1	47	Eli Lilly and Company
NCT03987919	A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes	completed	PHASE3	1,879	Eli Lilly and Company
NCT03940742	A Study of Tirzepatide in Participants With Impaired Liver Function	completed	PHASE1	32	Eli Lilly and Company
NCT03951753	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)	completed	PHASE1	117	Eli Lilly and Company
NCT03954834	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone	completed	PHASE3	478	Eli Lilly and Company
NCT03861052	A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes	completed	PHASE3	636	Eli Lilly and Company
NCT03882970	A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes	completed	PHASE3	1,444	Eli Lilly and Company
NCT03861039	A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes	completed	PHASE3	443	Eli Lilly and Company
NCT03730662	A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk	completed	PHASE3	2,002	Eli Lilly and Company
NCT03482024	A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function	completed	PHASE1	45	Eli Lilly and Company
NCT03375463	A Study of Tirzepatide (LY3298176) in Healthy Participants	completed	PHASE1	52	Eli Lilly and Company
NCT03322631	A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes	completed	PHASE1	48	Eli Lilly and Company
NCT03311724	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes	completed	PHASE2	111	Eli Lilly and Company
NCT03131687	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus	completed	PHASE2	318	Eli Lilly and Company
NCT02759107	A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)	completed	PHASE1	142	Eli Lilly and Company

Where to Participate: All Tirzepatide Trial Sites in the U.S. (394 sites across 42 states)

Every actively recruiting Tirzepatidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Digestive Health Specialists	Dothan36301	NCT06937086	Map
AL	Digestive Health Specialists	Dothan36301	NCT06937099	Map
AL	MFA Clinical Research	Tuscaloosa35405	NCT07165028	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale	Avondale85392	NCT06864026	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler	Chandler85225	NCT06864026	Map
AZ	The Institute for Liver Health II dba Arizona Clinical Trials - Chandler	Chandler85224	NCT07165028	Map
AZ	The Institute for Liver Health II dba Arizona Clinical Trials - Mesa	Chandler85225	NCT06143956	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff	Flagstaff86001	NCT06864026	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Gilbert	Gilbert85297	NCT06864026	Map
AZ	Spectrum Research Institute	Gilbert85297	NCT07165028	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale	Glendale85306	NCT06864026	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa	Mesa85210	NCT06864026	Map
AZ	The Institute for Liver Health II dba Arizona Liver Health - Peoria	Peoria85381	NCT07165028	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV	Phoenix85032	NCT06864026	Map
AZ	HOPE Research Institute	Phoenix85032	NCT06143956	Map
AZ	Medical Dermatology Specialists	Phoenix85006	NCT06857942	Map
AZ	Headlands Research - Scottsdale	Scottsdale85260	NCT06143956	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City	Sun City85351	NCT06864026	Map
AZ	Epic Medical Research-Sun City	Sun City85351	NCT07165028	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson	Tucson85704	NCT06864026	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast	Tucson85748	NCT06864026	Map
AZ	Del Sol Research Management, LLC	Tucson85715	NCT07165028	Map
AZ	The Institute for Liver Health II dba Arizona Clinical Trials - Tucson	Tucson85712	NCT07165028	Map
AZ	The Institute for Liver Health II dba Arizona Liver Health-Tucson	Tucson85712	NCT06143956	Map
AR	Arkansas Gastroenterology - North Little Rock	North Little Rock72117	NCT07165028	Map
CA	Smart Cures Clinical Research	Anaheim92806	NCT06937086	Map
CA	Smart Cures Clinical Research	Anaheim92806	NCT06937099	Map
CA	Medvin Clinical Research - Apple Valley	Apple Valley92307	NCT06864026	Map
CA	San Fernando Valley Health Institute	Canoga Park91304	NCT07165028	Map
CA	Medvin Clinical Research - Covina	Covina91722	NCT06864026	Map
CA	City of Hope Medical Center	Duarte91010	NCT07202247	Map
CA	Ark Clinical Research - Fountain Valley	Fountain Valley92708	NCT07165028	Map
CA	First OC Dermatology Research Inc	Fountain Valley92708	NCT06857942	Map
CA	Center For Dermatology Clinical Research, Inc.	Fremont94538	NCT06857942	Map
CA	Fresno Clinical Research Center	Fresno93720	NCT07165028	Map
CA	NorCal Medical Research, Inc	Greenbrae94904	NCT06143956	Map
CA	Newport Huntington Medical Group	Huntington Beach92648	NCT06864026	Map
CA	Velocity Clinical Research, Huntington Park	Huntington Park90255	NCT06143956	Map
CA	UCSD - Altman Clinical and Translational Research Institute (ACTRI)	La Jolla92037	NCT07165028	Map
CA	Purushotham & Akther Kotha MD, Inc	La Mesa91942	NCT06864026	Map
CA	Orange County Research Center	Lake Forest92630	NCT07165028	Map
CA	Om Research LLC	Lancaster93534	NCT07165028	Map
CA	Ark Clinical Research	Long Beach90815	NCT07165028	Map
CA	United Medical Doctors - Los Alamitos	Los Alamitos90720	NCT06937086	Map
CA	United Medical Doctors - Los Alamitos	Los Alamitos90720	NCT06937099	Map
CA	Keck School of Medicine, University of Southern California	Los Angeles90032	NCT06994338	Map
CA	Los Angeles Institute for Metabolic Research	Los Angeles90015	NCT07165028	Map
CA	Metropolis Dermatology	Los Angeles90017	NCT06857942	Map
CA	United Medical Doctors - Murrieta	Murrieta92563	NCT07165028	Map
CA	California Medical Research Associates	Northridge91324	NCT06937086	Map
CA	California Medical Research Associates	Northridge91324	NCT06937099	Map
CA	Northridge Clinical Trials	Northridge91325	NCT06857942	Map
CA	Knowledge Research Center	Orange92868	NCT07165028	Map
CA	Clinical and Translational Research Unit	Palo Alto94305	NCT05912621	Map
CA	Stanford University	Palo Alto94304	NCT06657209	Map
CA	California Liver Research Center	Pasadena91105	NCT07165028	Map
CA	Artemis Institute for Clinical Research	Riverside92503	NCT07165028	Map
CA	Medvin Clinical Research - Riverside	Riverside92508	NCT06864026	Map
CA	Peninsula Research Associates	Rolling Hills Estates90274	NCT06143956	Map
CA	Medical Associates Research Group	San Diego92123	NCT07165028	Map
CA	Rheumatology Center of San Diego	San Diego92128	NCT06864026	Map
CA	Quest Clinical Research	San Francisco94115	NCT07165028	Map
CA	Providence Saint John's Medical Foundation	Santa Monica90404	NCT06864026	Map
CA	Medvin Clinical Research - Temecula	Temecula92592	NCT06864026	Map
CA	Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute)	Torrance90502	NCT05708859	Map
CA	Medvin Clinical Research - Tujunga	Tujunga91042	NCT06864026	Map
CA	Diablo Clinical Research, Inc.	Walnut Creek94598	NCT06143956	Map
CA	Medvin Clinical Research - Whittier	Whittier90602	NCT06864026	Map
CO	University of Colorado - Anschutz Medical Campus	Aurora80045	NCT06582875	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT07165028	Map
CO	South Denver Gastroenterology	Englewood80113	NCT07165028	Map
CT	Stamford Therapeutics Consortium	Stamford06905	NCT06143956	Map
FL	K2 Medical Research WINTER GARDEN	Clermont34711	NCT07165028	Map
FL	K2 Medical Research - Daytona Beach	Daytona Beach32114	NCT07165028	Map
FL	Care Access - Delray Beach	Delray Beach33484	NCT07165028	Map
FL	AMR Clinical	Doral33172	NCT07165028	Map
FL	Northeast Research Institute (NERI)	Fleming Island32003	NCT06143956	Map
FL	Southwest General Healthcare Center	Fort Myers33907	NCT07165028	Map
FL	Indago Research & Health Center, Inc	Hialeah33012	NCT06143956	Map
FL	NeoClinical Research	Hialeah33016	NCT06857942	Map
FL	Encore Medical Research	Hollywood33024	NCT06857942	Map
FL	Encore Medical Research	Hollywood33024	NCT07165028	Map
FL	Skin Care Research	Hollywood33021	NCT06857942	Map
FL	Nature Coast Clinical Research - Inverness	Inverness34452	NCT07165028	Map
FL	Encore Borland-Groover Clinical Research	Jacksonville32256	NCT07165028	Map
FL	Gateway Community Services	Jacksonville32204	NCT06651177	Map
FL	Mayo Clinic in Florida	Jacksonville32224	NCT07218445	Map
FL	Health Awareness	Jupiter33458	NCT07165028	Map
FL	Vida Clinical Research	Kissimmee34741	NCT06864026	Map
FL	K2 MEDICAL Research THE VILLAGES	Lady Lake32159	NCT07165028	Map
FL	Florida Research Institute	Lakewood Rch34211	NCT07165028	Map
FL	Tampa Bay Medical Research - Largo	Largo33777	NCT07165028	Map
FL	Life Clinical Trials	Margate33063	NCT06864026	Map
FL	Evolution Clinical Trials	Miami33122-1722	NCT07165028	Map
FL	Gastro Health Research - Miami	Miami33176	NCT06937086	Map
FL	Gastro Health Research - Miami	Miami33176	NCT06937099	Map
FL	New Horizon Research Center	Miami33165	NCT06143956	Map
FL	Research Associates of South Florida - Miami - Southwest 8th Street	Miami33134	NCT06937086	Map
FL	Research Associates of South Florida - Miami - Southwest 8th Street	Miami33134	NCT06937099	Map
FL	University of Miami	Miami33136	NCT06774079	Map
FL	CZ Rheumatology	Miami Beach33140	NCT06864026	Map
FL	Floridian Clinical Research, LLC	Miami Lakes33016-1518	NCT07165028	Map
FL	GI PROS Research	Naples34102	NCT07165028	Map
FL	Suncoast Clinical Research, Inc.	New Port Richey34652	NCT06143956	Map
FL	Charter Research - Orlando	Orlando32803	NCT07165028	Map
FL	Charter Research - Winter Park	Orlando32803	NCT06143956	Map
FL	Digestive and Liver Center of Florida	Orlando32825	NCT06937086	Map
FL	Digestive and Liver Center of Florida	Orlando32825	NCT06937099	Map
FL	Headlands Research Orlando	Orlando32806	NCT07165028	Map
FL	Orlando Health	Orlando32806	NCT06937086	Map
FL	Orlando Health	Orlando32806	NCT06937099	Map
FL	Vitalia Medical Research	Palm Beach Gardens33410	NCT06864026	Map
FL	Gastro Health Research - Pensacola	Pensacola32504	NCT06937086	Map
FL	Gastro Health Research - Pensacola	Pensacola32504	NCT06937099	Map
FL	Progressive Medical Research	Port Orange32127	NCT07165028	Map
FL	Covenant Metabolic Specialists - Riverview	Riverview33578	NCT07165028	Map
FL	Care Access - St. Petersburg	St. Petersburg33710	NCT07165028	Map
FL	Precision Clinical Research	Sunrise33351	NCT06937086	Map
FL	Precision Clinical Research	Sunrise33351	NCT06937099	Map
FL	Care Access - Tamarac	Tamarac33321	NCT07165028	Map
FL	International Center for Research	Tampa33614	NCT06864026	Map
FL	MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research	Tampa33607	NCT06857942	Map
FL	Charter Research - Lady Lake	The Villages32162	NCT06143956	Map
FL	Covenant Metabolic Specialists, LLC	University Park34201	NCT07165028	Map
FL	TruDerm & TruSpa	Wellington33449	NCT06857942	Map
GA	Southeast Clinical Research Center	Dalton30720	NCT07165028	Map
GA	CenExel iResearch, LLC	Decatur30030	NCT06439277	Map
GA	Southeast Research Specialists	Douglasville30135	NCT06857942	Map
GA	Atlanta Research Center for Rheumatology	Marietta30060	NCT06864026	Map
GA	Gastrointestinal Specialists of Georgia	Marietta30060	NCT07165028	Map
GA	Rophe Adult and Pediatric Medicine/SKYCRNG	Union City30291	NCT07165028	Map
GA	Satilla Rheumatology & Internal Medicine	Waycross31501	NCT06864026	Map
HI	John A Burns School of Medicine	Honolulu96813	NCT06935838	Map
HI	Pacific Diabetes & Endocrine Center	Honolulu96817	NCT06143956	Map
ID	Medical Research Partners	Ammon83406	NCT06143956	Map
ID	Grand Teton Research Group	Idaho Falls83404	NCT06937086	Map
ID	Grand Teton Research Group	Idaho Falls83404	NCT06937099	Map
IL	Great Lakes Clinical Trials - Ravenswood	Chicago60640	NCT06143956	Map
IL	Great Lakes Clinical Trials - Ravenswood	Chicago60640	NCT06864026	Map
IL	Rush University Medical Center	Chicago60612	NCT06937086	Map
IL	Ruth M. Rothstein CORE Center	Chicago60612	NCT06651177	Map
IL	Greater Chicago Specialty Physicians	Schaumburg60195	NCT06864026	Map
IL	Arnold Arthritis & Rheumatology	Skokie60076	NCT06864026	Map
IL	NorthShore University Health System	Skokie60077	NCT06143956	Map
IL	Willow Rheumatology and Wellness PLLC	Willowbrook60527	NCT06864026	Map
IN	Dawes Fretzin Clinical Research Group, LLC	Indianapolis46250	NCT06857942	Map
IN	Indiana University Health University Hospital	Indianapolis46202	NCT06937086	Map
IN	Indiana University Health University Hospital	Indianapolis46202	NCT06937099	Map
IN	Indiana University Health University Hospital	Indianapolis46202	NCT07165028	Map
IN	Gastroenterology Health Partners	New Albany47150	NCT06937086	Map
IN	Gastroenterology Health Partners	New Albany47150	NCT06937099	Map
IN	Lake Cumberland Rheumatology	New Albany47150	NCT06864026	Map
IN	Deaconess Clinic- Gateway	Newburgh47630	NCT07165028	Map
IN	The Indiana Clinical Trials Center, PC	Plainfield46168	NCT06857942	Map
IN	Digestive Research Alliance of Michiana	South Bend46635	NCT07165028	Map
IA	Iowa Diabetes and Endocrinology Research Center	West Des Moines50266	NCT06143956	Map
IA	Iowa Diabetes and Endocrinology Research Center	West Des Moines50266	NCT07165028	Map
KS	AMR Clinical	El Dorado67042	NCT07165028	Map
KS	Johnson County Clinical Trials	Lenexa66219	NCT07165028	Map
KS	Cotton O'Neil Diabetes & Endocrinology	Topeka66606	NCT06143956	Map
KS	Cotton O'Neil Digestive Health Center	Topeka66606	NCT07165028	Map
KY	Equity Medical - Bowling Green	Bowling Green42104	NCT06857942	Map
KY	AMR Clinical	Lexington40509	NCT07165028	Map
KY	University of Kentucky	Lexington40506	NCT06721507	Map
KY	Gastroenterology Health Partners	Louisville40218	NCT06937086	Map
KY	Gastroenterology Health Partners	Louisville40218	NCT06937099	Map
KY	Monroe Biomedical Research - Louisville	Louisville40213	NCT06143956	Map
LA	Delta Research Partners of Bastrop, LLC	Bastrop71220	NCT07165028	Map
LA	Pennington Biomedical Research Center	Baton Rouge70808	NCT07154719	Map
LA	Accurate Clinical Research, Inc	Lake Charles70605	NCT06864026	Map
LA	Tandem Clinical Research	Marrero70072	NCT07165028	Map
LA	Care Access - New Iberia	New Iberia70560	NCT06937086	Map
LA	Care Access - New Iberia	New Iberia70560	NCT06937099	Map
LA	Care Access - New Iberia	New Iberia70560	NCT07165028	Map
LA	Louisiana Research Center	Shreveport71105	NCT06937086	Map
LA	Louisiana Research Center	Shreveport71105	NCT06937099	Map
LA	Louisiana Research Center	Shreveport71105	NCT07165028	Map
LA	Delta Research Partners of West Monroe	West Monroe71291	NCT07165028	Map
MD	Johns Hopkins University	Baltimore21146	NCT06847399	Map
MD	Mercy Medical Center - Baltimore	Baltimore21202	NCT07165028	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT07046819	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT07559500	Map
MD	Capital Digestive Care - Chevy Chase	Chevy Chase20815	NCT06937086	Map
MD	Capital Digestive Care - Chevy Chase	Chevy Chase20815	NCT06937099	Map
MD	Capital Digestive Care - Chevy Chase	Chevy Chase20815	NCT07165028	Map
MD	Klein & Associates, M.D., P.A.	Cumberland21502	NCT06864026	Map
MD	Klein & Associates, M.D., P.A.	Hagerstown21740	NCT06864026	Map
MD	Dermatology and Skin Cancer Specialists, LLC	Rockville20850	NCT06857942	Map
MA	Massachusetts General Hospital	Boston02114	NCT05933499	Map
MA	Massachusetts General Hospital Cancer Center	Boston02114	NCT07095517	Map
MA	Metro Boston Clinical Partners	Brighton02135	NCT06857942	Map
MA	Brigham and Women's Faulkner Hospital	Jamaica Plain02130	NCT06727331	Map
MA	Knownwell	Needham02492	NCT06143956	Map
MA	Lucida Clinical Trials	New Bedford02740	NCT06143956	Map
MA	Lucida Clinical Trials	New Bedford02740	NCT06937086	Map
MA	Lucida Clinical Trials	New Bedford02740	NCT06937099	Map
MA	Lucida Clinical Trials	New Bedford02740	NCT07165028	Map
MI	David Fivenson, MD, PLC	Ann Arbor48103	NCT06857942	Map
MI	University of Michigan	Ann Arbor48109	NCT07091734	Map
MI	Great Lakes Research Group, Inc.	Bay City48706	NCT06857942	Map
MI	The Derm Institute of West Michigan	Caledonia49316	NCT06857942	Map
MI	Clinical Research Institute of Michigan, LLC	Clinton Township48038	NCT07165028	Map
MI	Clinical Research Institute of Michigan, LLC	Saint Clair Shores48081	NCT06864026	Map
MI	Great Lakes Research Institute	Southfield48075	NCT07165028	Map
MI	Headlands Research - Detroit	Southfield48034	NCT06143956	Map
MI	Arcturus Healthcare , PLC, Troy Internal Medicine Research Division	Troy48098	NCT06143956	Map
MI	Arcturus Healthcare , PLC, Troy Internal Medicine Research Division	Troy48098	NCT07165028	Map
MN	MNGI Digestive Health	Minneapolis55413	NCT07165028	Map
MN	Children's Minnesota	Saint Paul55102	NCT06901245	Map
MS	GI Associates - GIA and Endoscopy Center - Flowood	Flowood39232	NCT07165028	Map
MO	The Gibson Center for Behavioral Change	Cape Girardeau63703	NCT06651177	Map
MO	StudyMetrix Research	City of Saint Peters63303	NCT06143956	Map
MO	AMR Clinical	Kansas City64114	NCT07165028	Map
MO	Clinvest Headlands Llc	Springfield65807	NCT06143956	Map
MO	Washington University School of Medicine	St Louis63110	NCT06937086	Map
MO	Washington University School of Medicine	St Louis63110	NCT06937099	Map
MO	Washington University School of Medicine	St Louis63110	NCT06976853	Map
MT	Logan Health Rheumatology	Kalispell59901	NCT06864026	Map
NV	Excel Clinical Research, LLC	Las Vegas89109	NCT07165028	Map
NV	Jubilee Clinical Research NV. LLC	Las Vegas89106	NCT07165028	Map
NV	Las Vegas Medical Research	Las Vegas89128	NCT06143956	Map
NV	Skin Cancer and Dermatology Institute - Reno	Reno89509	NCT06857942	Map
NH	Dartmouth-Hitchcock Medical Center	Lebanon03756	NCT06937086	Map
NH	Dartmouth-Hitchcock Medical Center	Lebanon03756	NCT06937099	Map
NH	Stracskin	Portsmouth03801	NCT06857942	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT06751589	Map
NJ	Psoriasis Treatment Center of Central New Jersey	East Windsor08520	NCT06857942	Map
NJ	Trinitas Comprehensive Cancer Center	Elizabeth07202	NCT06518837	Map
NJ	Tandem Clinical Research - Freehold	Freehold07728	NCT07165028	Map
NJ	Care Access - Hoboken	Hoboken07030	NCT06857942	Map
NJ	RWJBarnabas Health - Cooperman Barnabas, Livingston	Livingston07039	NCT06518837	Map
NJ	RWJBarnabas Health - Monmouth Medical Center	Long Branch07740	NCT06518837	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT06751589	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT06751589	Map
NJ	Rutgers Cancer Institute	New Brunswick08901	NCT06518837	Map
NJ	RWJBarnabas Health - Newark Beth Israel Medical Center	Newark07112	NCT06518837	Map
NJ	Clinical Research of Philadelphia	Pennington08534	NCT07165028	Map
NJ	The Cognitive and Research Center of New Jersey - Ridgewood	Ridgewood07450	NCT07165028	Map
NJ	RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset	Somerville08876	NCT06518837	Map
NJ	IMA Clinical Research Warren	Warren Township07059	NCT07165028	Map
NM	Southwest Gastroenterology Associates	Albuquerque87109	NCT07165028	Map
NM	University of New Mexico Health Sciences Center	Albuquerque87131	NCT06934642	Map
NY	Dent Neurologic Institute	Amherst14226	NCT06143956	Map
NY	Research Foundation of SUNY - University of Buffalo	Buffalo14203	NCT07165028	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT06751589	Map
NY	Velocity Clinical Research, Syracuse	East Syracuse13057	NCT06143956	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT06751589	Map
NY	Equity Medical	New York10023	NCT06857942	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06937086	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06976853	Map
NY	IMA Clinical Research Manhattan	New York10036	NCT07165028	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06751589	Map
NY	New York Gastroenterology Associates	New York10075	NCT06937086	Map
NY	New York Gastroenterology Associates	New York10075	NCT06937099	Map
NY	New York Gastroenterology Associates	New York10075	NCT07165028	Map
NY	North Suffolk Neurology	Port Jefferson Station11776	NCT06143956	Map
NY	Rochester Clinical Research, LLC	Rochester14609	NCT06143956	Map
NY	University of Rochester Medical Center	Rochester14642	NCT06864026	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT06751589	Map
NY	Care Access - Yonkers	Yonkers10701	NCT06937086	Map
NY	Care Access - Yonkers	Yonkers10701	NCT06937099	Map
NY	Care Access - Yonkers	Yonkers10701	NCT07165028	Map
NC	Revival Research Institute, LLC	Cary27511	NCT06857942	Map
NC	Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT07065552	Map
NC	Coastal Research Institute - Fayetteville	Fayetteville28304	NCT06937086	Map
NC	Coastal Research Institute - Fayetteville	Fayetteville28304	NCT06937099	Map
NC	Medication Management	Greensboro27405	NCT06143956	Map
NC	Onsite Clinical Solutions - Huntersville	Huntersville28078	NCT06857942	Map
NC	Monroe Biomedical Research	Monroe28112	NCT06143956	Map
NC	Monroe Biomedical Research	Monroe28112	NCT07165028	Map
NC	Carteret Medical Group	Morehead City28557	NCT07165028	Map
NC	Lucas Research, Inc	Morehead City28557	NCT06143956	Map
NC	Lucas Research, Inc.	New Bern28562	NCT06143956	Map
NC	Onsite Clinical Solutions, LLC - Brenner Ave	Salisbury28144	NCT06864026	Map
OH	Akron Gastro Research	Akron44320	NCT07165028	Map
OH	Optima Research - Boardman	Boardman44512	NCT06857942	Map
OH	CTI Clinical Research Center	Cincinnati45212	NCT06143956	Map
OH	Cleveland Clinic	Cleveland44195	NCT06802081	Map
OH	Paramount Medical Research & Consulting, LLC	Middleburg Heights44130	NCT06864026	Map
OH	CRIOH	Westlake44145	NCT07165028	Map
OH	Gastro Intestinal Research Institute of Northern Ohio, LLC	Westlake44145	NCT06937086	Map
OH	Gastro Intestinal Research Institute of Northern Ohio, LLC	Westlake44145	NCT06937099	Map
OK	Essential Medical Research	Tulsa74137	NCT06864026	Map
OR	Oregon Dermatology and Research Center	Portland97210	NCT06857942	Map
PA	US Digestive Health - Flourtown	Flourtown19031	NCT07165028	Map
PA	Thomas Jefferson University - Medicine/GI and Hepatology	Philadelphia19107	NCT06937086	Map
PA	Thomas Jefferson University - Medicine/GI and Hepatology	Philadelphia19107	NCT06937099	Map
PA	Dermatology Associates of Plymouth Meeting	Plymouth Meeting19462	NCT06857942	Map
PA	US Digestive Health - Wyomissing	Wyomissing19610	NCT07165028	Map
RI	University Gastroenterology	Providence02905	NCT06937086	Map
RI	University Gastroenterology	Providence02905	NCT06937099	Map
RI	University Gastroenterology	Providence02905	NCT07165028	Map
SC	Columbia Dermatology & Aesthetics	Columbia29212	NCT06857942	Map
SC	Columbia Digestive Health Research	Columbia29204	NCT07165028	Map
SC	Gastroenterology Associates - Patewood	Greenville29607	NCT06937086	Map
SC	Gastroenterology Associates - Patewood	Greenville29607	NCT06937099	Map
SC	Prisma Health	Greenville29605	NCT06651177	Map
SC	Tribe Clinical Research, LLC	Greenville29607	NCT06143956	Map
TN	Galen Medical Group - Galen Hepatology	Chattanooga37421	NCT07165028	Map
TN	Gastro One (Walnut Run Road)	Cordova38018	NCT07165028	Map
TN	Gastroenterology Center Of The Midsouth	Cordova38018	NCT06937086	Map
TN	Gastroenterology Center Of The Midsouth	Cordova38018	NCT06937099	Map
TN	West Tennessee Research Institute	Jackson38305	NCT06864026	Map
TN	St. Jude Children's Research Hospital	Memphis38105	NCT07228741	Map
TN	AARA Clinical Research - Murfreesboro Medical Clinic	Murfreesboro37128	NCT06864026	Map
TN	Quality Medical Research	Nashville37211	NCT06143956	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06651177	Map
TN	Vanderbilt University Medical Center	Nashville37203	NCT06901245	Map
TN	DelRicht Research - Thompson's Station	Smyrna37167	NCT06857942	Map
TX	American Research Corporation	Austin78757	NCT07165028	Map
TX	IMA Clinical Research Austin	Austin78745	NCT06143956	Map
TX	IMA Clinical Research Austin	Austin78745	NCT07165028	Map
TX	Pinnacle Clinical Research	Austin78757	NCT07165028	Map
TX	Bellaire Clinical Research	Bellaire77401	NCT07165028	Map
TX	Bellaire Dermatology Associates	Bellaire77401	NCT06857942	Map
TX	Headlands Horizons, LLC dba Headlands Research-Brownsville	Brownsville78526	NCT07165028	Map
TX	South Texas Research Institute - Brownsville	Brownsville78520	NCT07165028	Map
TX	Precision Comprehensive Clinical Research Solutions - Colleyville	Colleyville76034	NCT06864026	Map
TX	Baylor University Medical Center, Baylor Charles A Sammons Cancer Center	Dallas75246	NCT06517212	Map
TX	FutureSearch Trials of Dallas	Dallas75251	NCT06143956	Map
TX	Modern Research Associates, PLLC	Dallas75231	NCT06857942	Map
TX	Velocity Clinical Research, Dallas	Dallas75230	NCT06143956	Map
TX	Soma Clinical Trials	Denison75020	NCT07165028	Map
TX	Epic Medical Research - DeSoto	DeSoto75115	NCT07165028	Map
TX	South Texas Research Institute	Edinburg78539	NCT07165028	Map
TX	Dallas Research Institute	Farmers Branch75234	NCT07165028	Map
TX	Care United Research, LLC	Forney75126	NCT07165028	Map
TX	AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Fort Worth	Fort Worth76109	NCT06864026	Map
TX	GI Alliance - Fort Worth	Fort Worth76104	NCT07165028	Map
TX	Accurate Clinical Research, Inc	Houston77089	NCT06864026	Map
TX	Biopharma Informatic, LLC	Houston77084	NCT07165028	Map
TX	Care Access - Houston	Houston77054	NCT07165028	Map
TX	Center for Clinical Studies	Houston77004	NCT06857942	Map
TX	Houston Research Institute	Houston77079	NCT07165028	Map
TX	HRI- Medical Center	Houston77004	NCT07165028	Map
TX	PlanIt Research, PLLC	Houston77079	NCT06143956	Map
TX	Research Physicians Network, LLC	Houston77089	NCT06864026	Map
TX	Research Physicians Network, LLC	Houston77089	NCT07165028	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT06759701	Map
TX	AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Irving	Irving75039	NCT06864026	Map
TX	Biopharma Informatic, LLC	Katy77494	NCT06864026	Map
TX	Biopharma Informatic, LLC	McAllen78503	NCT07165028	Map
TX	DHR Health Institute for Research and Development (Administrative Office & Laboratory)	McAllen78504	NCT07165028	Map
TX	Southern Endocrinology Associates	Mesquite75149	NCT07165028	Map
TX	HRI Pasadena	Pasadena77505	NCT07165028	Map
TX	Austin Institute for Clinical Research	Pflugerville78660	NCT06857942	Map
TX	American Research Corporation at Texas Liver Institute	San Antonio78215	NCT07165028	Map
TX	Clinical Trials of Texas, LLC dba Flourish Research	San Antonio78229	NCT07165028	Map
TX	Endeavor Clinical Trials	San Antonio78240	NCT06143956	Map
TX	Gastroenterology Research of San Antonio	San Antonio78229	NCT06937086	Map
TX	Gastroenterology Research of San Antonio	San Antonio78229	NCT06937099	Map
TX	IMA Clinical Research San Antonio	San Antonio78229	NCT07165028	Map
TX	Southern Star Research Institute	San Antonio78229	NCT06937086	Map
TX	Southern Star Research Institute	San Antonio78229	NCT06937099	Map
TX	Tekton Research - Fredericksburg Road	San Antonio78258	NCT06143956	Map
TX	Texas Dermatology and Laser Specialists	San Antonio78218	NCT06857942	Map
TX	University Health System Texas Diabetic Institute	San Antonio78207	NCT06246799	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT06811324	Map
TX	UT Health Science Center	San Antonio78229	NCT06246799	Map
TX	Consano Clinical Research, LLC	Shavano Park78231	NCT07165028	Map
TX	GI Alliance - Southlake	Southlake76092	NCT07165028	Map
TX	Houston Research Institute (HRI) - Sugar Land	Sugar Land77479	NCT07165028	Map
TX	Advanced Rheumatology of Houston - Woodlands	The Woodlands77382	NCT06864026	Map
TX	DM Clinical Research - TRA	Tomball77375	NCT06864026	Map
TX	Tyler Research Institute	Tyler75701	NCT06937086	Map
TX	Tyler Research Institute	Tyler75701	NCT06937099	Map
TX	Center for Clinical Studies	Webster77598	NCT06857942	Map
TX	Texas Valley Clinical Research	Weslaco78596	NCT06143956	Map
TX	Texas Valley Clinical Research	Weslaco78596	NCT07165028	Map
TX	Medrasa Clinical Research	Wylie75098	NCT07165028	Map
UT	Tanner Clinic	Layton84041	NCT06857942	Map
UT	Care Access - Ogden	Ogden84403	NCT07165028	Map
UT	University of Utah	Salt Lake City84108	NCT06651177	Map
UT	Advanced Research Institute - Sandy	Sandy City84070	NCT07165028	Map
VA	Sovah Clinical Research-River District	Danville24541	NCT06143956	Map
VA	Eximia Research - Norfolk	Norfolk23502	NCT07165028	Map
VA	Richmond Veterans Affairs Medical Center (Richmond VA Medical Center)	Richmond23249	NCT07165028	Map
VA	Gastroenterology Consultants of Southwest Virginia	Roanoke24014	NCT06937086	Map
VA	Gastroenterology Consultants of Southwest Virginia	Roanoke24014	NCT07165028	Map
WA	Bellevue Dermatology Clinic	Bellevue98104	NCT06857942	Map
WA	Washington Gastroenterology - Bellevue	Bellevue98004	NCT07165028	Map
WA	Dermatology of Seattle	Burien98168	NCT06857942	Map
WA	Seattle Children's Hospital	Seattle98105	NCT06901245	Map
WA	Seattle Rheumatology Associates PLLC	Seattle98104	NCT06864026	Map
WA	UW Medicine Diabetes Institute	Seattle98109	NCT07165028	Map
WA	Arthritis Northwest, PLLC	Spokane Valley99216	NCT06864026	Map
WA	Washington Gastroenterology - Tacoma	Tacoma98405	NCT06937086	Map
WA	Washington Gastroenterology - Tacoma	Tacoma98405	NCT06937099	Map
WA	Central Washington Health Services Association d/b/a Confluence Health	Wenatchee98801	NCT06143956	Map
WV	CAMC Health Education and Research Institute Inc	Charleston25304	NCT07165028	Map
WV	Marshall Health	Huntington25701	NCT06651177	Map
WV	Healthy Minds/Chestnut Ridge	Morgantown26505	NCT06651177	Map
WI	Wisconsin Center for Advanced Research	Milwaukee53215	NCT06937086	Map
WI	Wisconsin Center for Advanced Research	Milwaukee53215	NCT06937099	Map

Browse Tirzepatide Trials by State

Texas clinical trials New York clinical trials Florida clinical trials Illinois clinical trials Arizona clinical trials Indiana clinical trials South Carolina clinical trials California clinical trials Tennessee clinical trials Massachusetts clinical trials

tirzepatideobesityoverweighttype 2 diabetesdiabetes mellitus, type 2healthyclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated May 12, 2026.

Recent Tirzepatide updates

What Is Tirzepatide?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Tirzepatide Development Timeline

Conditions Under Study

All Tirzepatide Clinical Trials (190)

Sponsors

Where to Participate: All Tirzepatide Trial Sites in the U.S. (394 sites across 42 states)

Browse Tirzepatide Trials by State